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The current outcomes of peri-hilar cholangiocarcinoma (PH-CCA) are in general 
poor with no proven roles for any treatment modalities in improving survival apart 
from complete surgical extirpation. The dismal prognosis observed is contributed to 
by both delays in diagnosis and aggressive tumour biology. The advent of molecular 
targeting of solid cancers allows harnessing this property on microbubble and 
nanotechnology based platforms. Such a system provides for concurrent diagnosis 
and therapeutic effect (theragnosis), the feasibility of which is explored in this work. 
 
The expression of two candidate biomarkers with established roles in cancer 
progression, namely Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Matrix 
Metalloproteinase-9 (MMP9) were examined by Immunohistochemistry in 54 human 
samples of resected PH-CCA. These markers were then evaluated for their 
potential as molecular targets in theragnostic platforms in cholangiocarcinoma. 
 
Both NGAL and MMP9 were found to be abundantly expressed in both tumour 
tissue and control liver. Although higher NGAL expression was associated with 
nodal metastases, no prognostic impact was seen for either marker. NGAL 
expression was further interrogated in six cholangiocarcinoma cell lines by Western 
blotting, Immunofluorescence and ELISA techniques, which revealed localisation of 
NGAL to the cell membrane and its secretion, both indicating its suitability to a 
targeting platform. Nonetheless, its expression in normal liver tissue could lead to 
off-target effects. 
 
Concurrently, the expression of vascular ligands CD31, CD105 and Vascular 
Endothelial Growth Factor Receptor-2 were each assessed in the same cohort of 
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tissue samples. CD105 expression was found to be independently predictive of 
poorer overall survival. Subsequent in vitro flow assay experiments using CD105 
antibody conjugated microbubbles showed it bound murine SVR endothelial cells 
significantly more in comparison to isotype control microbubbles. Furthermore, 
evaluation of in vivo targeting with the aid of high frequency ultrasound 
demonstrated CD105-microbubbles bound to tumour endothelium significantly more 
than control microbubbles in a subcutaneous murine xenograft model of 
cholangiocarcinoma. 
 
This work therefore indicates NGAL is suited to a theragnostic approach in 
cholangiocarcinoma although larger data sets are required to explore its prognostic 
impact. CD105-microbubbles could be utilised in the delivery of such theragnostic 
particles to cholangiocarcinoma tissue, whilst in themselves providing a non-
invasive index of tumour vascularity when imaged with ultrasound.
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Cholangiocarcinoma (CCA) is an aggressive cancer of the biliary tract arising from 
malignant transformation of bile duct epithelium (Esposito and Schirmacher, 2008). 
Categorized broadly into intra-hepatic (IH-CCA) and extra-hepatic (EH-CCA) forms, 
it is endemic in Far East Asia but assuming an increasing global relevance. With a 
median survival of 3.9 months from diagnosis in the absence of treatment (Park et 
al., 2009), the adverse outcomes for CCA are disconcerting given the increasing 
incidence of CCA, particularly in Western nations (Blechacz and Gores, 2008a).  
Hallmarks of the disease include late detection and poor prognosis, which have not 
been seen any significant improvements in recent decades.  Resectional surgery 
and, on occasion, liver transplantation (Darwish Murad et al., 2012) provide the only 




CCA accounts for 10- 15% of primary liver cancers worldwide and ranks second in 
incidence to Hepatocellular Carcinoma (HCC) (Blechacz and Gores, 2008a). Extra-
hepatic CCA is the commoner type of this tumour and accounts for up to 90% of all 
CCA cases (Blechacz and Gores, 2008b). 
 
The prevalence of CCA varies globally (Figure 1). Nations in South East Asia 
encounter the bulk of the disease (Shaib and El-Serag, 2004; Khan et al., 2008), 
reflecting regional differences in aetiological factors and pathogenesis. In the West, 




Figure 1: Worldwide incidence (per 100,000) of CCA 
(From Banales et al. Expert consensus document: Cholangiocarcinoma: current knowledge 
and future perspectives consensus statement from the European Network for the Study of 
Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261–280. 
DOI:10.1038/nrgastro.2016.51. Used under a Creative Commons Attribution 4.0 
International License (http://creativecommons.org/licenses/by/4.0/) 
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of EH-CCA has remained static or declined (Patel, 2002; Welzel et al., 2006; West 
et al., 2006; Blechacz and Gores, 2008a), for reasons that are not entirely clear 
(Figure 2). However, it must be noted that this phenomenon is at least in part 
attributable to the misclassification of peri-hilar cholangiocarcinoma (PH-CCA) as 
IH-CCA in the 2nd edition of the International Classification of Diseases for Oncology 
(ICD-O-2), issued in 1990 (Welzel et al., 2006). This error has only been partially 
addressed in the 3rd edition of this classification (ICD-O-3) published in 2000, which 
allows PH-CCA to be categorized into either IH-CCA or EH-CCA groups. 
 
Keeping this fact in mind, data from the United States has revealed the age-
adjusted incidence of IH-CCA to be increasing, with rates of 0.85/100,000 over the 
period 1995-99 (Patel, 2001). In the United Kingdom (England & Wales), IH-CCA 
incidence from 1999- 2001 was 1.33 and 1.06 per 100,000 in men and women 
respectively (West et al., 2006). Statistics from the Far East from 1998- 2002 show 
considerable heterogeneity in CCA occurrence between nations of the region. The 
highest rates of IH-CCA are seen in Thailand (averaging between 0.5- 8.2/100,000 
across both sexes), whilst Korea has the highest incidence of EH-CCA, of 3.6 and 
2.6/100,000 in men and women respectively. Nations such as China, Vietnam and 
Philippines have similar rates of CCA to Western countries (Shin et al., 2010a). 
 
The mean age at presentation is 50 years worldwide, although Western data 
suggests a peak in the seventh decade of life (Blechacz and Gores, 2008a; Khan et 
al., 2008; Gatto and Alvaro, 2010).  There is a male preponderance globally with 


























Figure 2: Differences in incidence of IH-CCA and EH-CCA worldwide.  
(From Bragazzi et al. Cholangiocarcinoma: Epidemiology and risk factors. Transl 
Gastrointest Cancer 2012; 1:21-32. DOI: 10.3978/j.issn.2224-4778.2011.11.04). 
Reproduced with permission from the publisher. 
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1.1.2 Relevant hepatic anatomy 
 
The liver is the largest solid organ in the body, and occupies the right upper 
quadrant region of the abdomen. Topographically it is demarcated into a larger right 
lobe and a smaller left lobe based on the attachment of the Falciform ligament to its 
anterior surface, and in adults the organ weighs  approximately 2% of total body 
weight (Urata et al., 1995). The vasculature of the liver consists broadly of the portal 
vein and hepatic artery (comprising the hepatic inflow vessels) and three hepatic 
veins which provide venous drainage into the vena cava. The liver hilum is the area 
at which the inflow vessels branch and enter the parenchyma, and also has the bile 
duct with its first-order branches viz. left and right hepatic ducts running through it. 
This particular intimate spatial configuration of all these structures is relevant to the 
poor resectability rates seen in PH-CCA, as this cancer can easily involve these 
important inflow vessels (Figure 3). 
 
The most popular anatomical classification of the liver is that of Couinaud, who 
proposed subdivision of the hepatic parenchyma into eight segments, as shown in 
Figure 4 (Couinaud, 1957). This particular system has the most relevance from a 
surgical standpoint, as each segment is supplied with its own branch of the portal 
vein, hepatic artery and hepatic vein. 
 
At a microscopic level, the liver parenchyma is organised into polygonal hepatic 
lobules (Figure 5). These consist of sheets of hepatocytes (cords) centred on a 
terminal branch of the hepatic vein, called the central vein. Portal tracts, which 
comprise a branch of the portal vein, hepatic artery and bile duct along with 
lymphatics, are found at the periphery of lobules (Figure 6). In contrast, the hepatic 
acinus (the functional unit of the liver) consists of a portal tract at its centre and is 




Figure 3: Cut-away section of the central portion of the liver showing the compact 
arrangement of structures at the liver hilum 
 From Chamberlain RS. Essential Functional Hepatic and Biliary Anatomy for the Surgeon. 
In Hepatic Surgery 2013, Abdeldayem H (Ed), InTech, DOI: 10.5772/53849. Used under the 




Figure 4: Couinaud’s segmental anatomy of the liver 
 A total of eight segments are seen, each having its own branch of inflow and outflow 
vessels, and biliary drainage.  
From Chamberlain RS. Essential Functional Hepatic and Biliary Anatomy for the  
Surgeon. In Hepatic Surgery 2013, Abdeldayem H (Ed), InTech, DOI: 10.5772/53849. Used 

























Figure 5: The functional unit of the liver 
Schematic diagram showing the microscopic arrangement of liver parenchyma into a 
classical lobule and the functional unit termed the hepatic acinus. Hepatic parenchymal 
zones corresponding to periportal, mid and pericentral areas are numbered 1 to 3. Blood 
entering the portal tract flows along these zones in succession via endothelial cell lined 
channels (hepatic sinusoids) becoming progressively deoxygenated and nutrient depleted 
as it drains towards the central vein (Krishna, 2013)  
From https://www.flickr.com/photos/mitopencourseware/3694426132 and used under the 





























Figure 6: Microscopic arrangement of blood flow within the liver parenchyma  
Diagram showing mixing of portal venous and hepatic arterial blood along the hepatic 
sinusoids before collecting into the central vein. A liver-specific systemically administered 
theragnostic agent would gain access to liver parenchyma via these sinusoids. 
From https://commons.wikimedia.org/wiki/File:Hepatic_structure2.svg and used under the 







Although CCA is classified broadly as being intra-hepatic or extra-hepatic in type, 3 
topographical forms are recognised in an effort to improve clinical applicability: intra-
hepatic, peri-hilar (Klatskin) and distal (Nakeeb et al., 1996; Esposito and 
Schirmacher, 2008; Ebata et al., 2009) as represented in Figure 7. PH-CCA has 
been variably defined, viz. extra-hepatic bile duct cancers within 2 cms of the 
common hepatic duct bifurcation (Aljiffry et al., 2009; Cardinale et al., 2010), and 
alternatively those actually involving the hepatic duct bifurcation (Nakeeb et al., 
1996).  A more contemporary definition of PH-CCA encompasses tumours proximal 
to the origin of the cystic duct up to second-generation tributaries of the left and 
right hepatic ducts (Deoliveira et al., 2011). Regardless, peri-hilar tumours are the 
most frequent type of CCA, accounting for 50-70% of all cases (Nakeeb et al., 1996; 
Khan et al., 2002; DeOliveira et al., 2007a). Approximately 20-30% of CCAs are of 
the distal extra-hepatic variety whereas 5-10% are within the liver (IH-CCA) (Aljiffry 
et al., 2009). 
 
A popular classification for PH-CCA is that proposed by Bismuth and Corlette 
(Bismuth and Corlette, 1975) though this system is simplistic and does not factor in 







Figure 7:Topographical representation of all three forms of CCA 
Schematic diagram showing the liver (brown borders) superimposed on 
the biliary tree and gall bladder (green borders). The 3 types of CCA (IH-




Figure 8: Bismuth-Corlette classification of PH-CCA 
Type 1 tumours are confined to the common hepatic duct whereas Type 2 lesions involve 
the biliary confluence. Type 3 tumours are subdivided based on whether they additionally 
involve the right (3A) or left hepatic duct (3B). Lastly, Type 4 cancers affect the confluence 
and extend up both ducts. From http://radiopaedia.org/cases/diagram-bismuth-corlette-
classification-of-perihilar-cholangiocarcinoma (Matt Skalski). Used under the Creative 




1.1.4 Risk factors 
 
Common risk factors for CCA are shown in Table 1. Regional variations in aetiology 
exist, with the prevalent cause in South East Asia being parasitic infestations of the 
liver (Shin et al., 2010b). In the West, CCA shares a close association with primary 
sclerosing cholangitis (PSC), although around 90% of patients do not have any 
attributable risk factor at the time of diagnosis (Ben-Menachem, 2007). However, all 
risks converge to a scenario of chronic inflammation of bile ducts and biliary stasis, 
which appear to be the final common denominators leading to CCA development 
(Cardinale et al., 2010; Gatto and Alvaro, 2010). 
 
1.1.5 Pathology 
1.1.5.1 Gross Pathology 
 
Macroscopic growth patterns of IH-CCA have been categorized into mass forming 
(MF), peri-ductal infiltrating (PI) and intra-ductal growth (IG) types by the Liver 
Cancer Study Group of Japan (Yamasaki, 2003). MF CCA tends to originate from 
smaller bile ducts and is hence found peripherally within the liver. In contrast, CCA 
arising from larger ducts (and therefore more central in location, towards the hilar 
region) can be of the PI, MF or IG type (Nakanuma et al., 2010). Mass forming 
tumours are the most common phenotypic variant of IH-CCA and have the worst 
prognosis too (Sirica et al., 2009). IG type CCA is the rarest of the three and carries 






Risk factors for development of Cholangiocarcinoma  
Primary Sclerosing Cholangitis 
Liver fluke infestation (Opisthorchis viverrini, Clonorchis sinensis) 
Hepatolithiasis 
Choledochal cysts, Carolis’ disease 
Hepatitis B, C 
Cirrhosis 
Obesity, Non-insulin dependent Diabetes 
Toxins (Thorotrast) 
Alcohol 
Genetic polymorphisms  
Surgical biliary-enteric drainage 
 
 
Table 1: Risk factors for CCA 






MF CCA appears to the naked eye appear as firm to hard whitish masses, usually 
in the background of non-cirrhotic liver tissue. Satellite nodules are occasionally 
seen and extensive tumour necrosis is not a predominant feature (Esposito and 
Schirmacher, 2008). The PI variant grows axially along affected bile ducts often 
causing associated stricturing, whereas the IG type tends to show polypoid or 
papillary tumour projections into the bile duct lumen (Nakanuma et al., 2010). 
 
EH-CCA grossly takes on a whitish, fibrotic and scarred appearance, and in the 
peri-hilar region invasion of adjacent liver parenchyma may be a feature. On the 
background of PSC, dense fibrosis may make appreciation of tumour tissue difficult 
outwith, although neoplastic ingrowth into the biliary lumen may be apparent on 




Histologically CCAs are usually adenocarcinomas of varying grade, though rare 
variants such as squamous, mucinous and clear cell types have also been 
described. Background desmoplasia is often seen, as is perineural and 




Local spread of CCA can occur by several routes viz. longitudinally along the bile 
duct, via nerve sheaths (perineural spread) and radially into adjacent structures 
(Esposito and Schirmacher, 2008). In IH-CCA, invasion of adjoining liver 
vasculature can lead to intra-hepatic metastases, whereas peritoneal dissemination 
may be a result of serosal involvement, especially in EH-CCA. Regional lymph 
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nodal metastases are encountered in excess of 30% cases (Kitagawa et al., 2001; 
de Jong et al., 2011b), more so with advancing tumour stage, periductal infiltrating 
type and poorer cell differentiation (Choi et al., 2009). Nodes in the pericholedochal 
region and hepatoduodenal ligament are most often the first to be involved, followed 
by those in the para-aortic area. Distant metastases are a late feature with reported 





Accurate staging of a cancer at diagnosis serves to provide individual prognostic 
information and guides therapy, whilst helping standardise and inform existing and 
future treatment protocols worldwide. Cholangiocarcinoma has varying clinical 
behaviour based on its location and this is reflected in the different staging systems 
that are in place for each subtype of this cancer. 
The most widely used staging system in CCA is that proposed by the American 
Joint Cancer Committee (AJCC) and adopted by the Union for International Cancer 
Control (UICC) and is based on the characteristics of the primary tumour (T), state 
of  regional lymph nodes (N) and the presence of metastatic disease (M), together 
known as the TNM stage. The latest (7th) edition of the AJCC cancer manual issued 
in 2009 incorporates important changes to its predecessor from 2002 with respect 
to CCA staging (Edge and American Joint Committee on Cancer., 2010): 
 In IH-CCA, tumour size no longer contributes to T stage. Tumours breaching 
visceral peritoneum or invading adjacent structures are now included under 
T3 stage rather than T4. In the 7th edition, T4 tumours are those which 
exhibit features of periductal invasion. 
 PH-CCA (Table 2) and EH-CCA have both been given dedicated staging 
systems, which is in contrast to the previous edition where they were both  
 36 
 
Primary tumour (T) 
Tx Primary Tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour confined to the bile duct, with extension up to the muscle layer 
or fibrous tissue 
T2a Tumour invades beyond the wall of the bile duct to surrounding adipose 
tissue 
T2b Tumour invades adjacent hepatic parenchyma 
T3 Tumour invades unilateral branches of the portal vein or hepatic artery 
T4 Tumour invades main portal vein or its branches bilaterally; the common 
hepatic artery; the second-order biliary radicals bilaterally; or the second-
order biliary radicals unilaterally, with contralateral portal vein or hepatic 
artery involvement  
 
Regional lymph nodes (N) 
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis (including nodes along the cystic duct, 
common bile duct, hepatic artery, and portal vein) 
N2 Metastasis to peri-aortic, peri-caval, superior mesenteric artery, and/or 
celiac artery lymph nodes 
 
Distant metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
 
Stage grouping 
Stage 0 Tis N0 M0 
Stage 1 T1 N0 M0 
Stage II T2a/b N0 M0 
Stage IIIA T3 N0 M0 
Stage IIIB T1-3 N1 M0 
Stage IVA T4 N0-1 M0 
Stage IVB Any T N2 M0 
Any T Any N M1 
 
Table 2: TNM staging for PH-CCA  
(adapted from 7
th
 edition of the AJCC manual) 
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clubbed under the label of Extrahepatic bile duct cancer. Stage IV disease in 
PH-CCA now denotes non-resectability, as opposed to Stage III disease in 






The lack of effective modalities to enable timely diagnosis of CCA or permit 
screening for the condition has led to extensive research on this front. A number of 
potential biomarkers (Table 3) have been identified over recent years by analysis of 
serum, bile and tumour tissue (Alvaro, 2009). Though many have shown potential in 
terms of applicability, only a minority of these markers have as yet found 
widespread use in clinical practice at present, with none specific for CCA.  
 
Serum Carbohydrate Antigen 19-9 (CA 19-9) remains the most popular biomarker 
currently in use for CCA diagnosis (Alvaro, 2009; Gatto and Alvaro, 2010; Gatto et 
al., 2010). The sensitivity and specificity of CA 19-9 measurements in diagnosing 
CCA is however subject to wide variation, dependent on the population under 
scrutiny and the cut-off values assigned as significant. 
 
In biliary obstruction, biliary levels of insulin-like growth factor-1 (IGF-1) have been 
shown to be 15-20 times higher in EH-CCA patients than in those with pancreatic 
cancer or benign biliary disorders (Alvaro et al., 2007). Encouragingly, both the 
sensitivity and specificity for biliary IGF-1 in diagnosing EH-CCA was 100% and in 
contrast, serum IGF-1 levels were comparable between these 3 groups. As yet, 





















Marker Sensitivity % Specificity % 
Serum   
Carbohydrate Antigen 19-9 (CA 19-9) 53-92 50-98 
Carcino-embryonic Antigen (CEA) 33-68 79-100 
Interleukin-6 73 92 
Bile   
CA 19-9 46-61 60-70 
Carcino-embryonic Antigen (CEA) 67-84 33-80 
Insulin-like Growth Factor (IGF-1) 100 100 
Tissue   
Cytokeratin-7 78-100 - 
Cytokeratin-19 44-80 - 
Table 3: Notable biomarkers in CCA 
(Alvaro, 2009; Chan and Yeh, 2010). Aggregate sensitivities and specificities for each 




A variety of imaging options are used in CCA (Table 4), reflective of the differing 
utilities of these modalities in diagnosing this cancer. In routine practice, 
Computerized Tomography (CT) and Magnetic Resonance Cholangio-







Surgical removal of the tumour offers the only means for cure of CCA and though 
resectability rates generally remain low, they vary from 18-70% (Morise et al., 
2010). The more proximal the location of the tumour up the biliary tree, the higher 
the incidence of non-resectability at diagnosis (Nakeeb et al., 1996). CCA is prone 
to local recurrence, a phenomenon most likely explained by metastatic regional 
nodal disease or microscopic tumour burden at resection margins at the time of 
surgery. Despite surgery, clear resection margin (R0) rates are often less than 50% 
(Meza-Junco et al., 2010). Therefore although much attention is currently focused 
on earlier diagnosis, it is paramount that negative surgical margins be achieved for 



































Imaging modality Main utility Reference 
Transabdominal Ultrasonography 
Screening for cholestasis,  
intrahepatic lesions 
(Choi et al., 2004) 
Endoscopic& Intraductal 
Ultrasonography 
Assessment of tumour size 
(Garrow et al., 2007; 
Tamada et al., 2011) 
Endoscopic Retrograde 
Cholangiography 
Tissue biopsy,  
therapeutic duct decompression 
(Aljiffry et al., 2009) 
Cholangioscopy Direct visualization and biopsy (Tamada et al., 2011) 
Computerized Tomography Loco-regional & distant spread (Vilgrain, 2008) 
Magnetic Resonance 
Cholangiography 
Tumour size (Kaltenthaler et al., 2006) 
Positron Emission Tomography 
Indeterminate lesions,  
distant spread 





The rates of resectability in IH-CCA are disappointing, ranging from 18-70% (Morise 
et al., 2010). As for other types of CCA, the intra-hepatic variety mandates complete 
excision in order to improve survival. Given the propensity for IH-CCA to have 
associated satellite nodules, anatomical (segmental) resections are frequently 
required, which also remains the need in larger tumours. The recommended width 
of tumour-free margin has been a matter of debate, and presently no agreement 
exists (Agrawal and Belghiti, 2011). However, there is consensus that 
microscopically negative margins be achieved (Nathan and Pawlik, 2010) and with 
smaller tumour size, a non-anatomical/wedge resection should therefore suffice 
provided this requirement is satisfied. Five-year survival rates after hepatectomy for 
IH-CCA are 20-40% with adverse prognostic markers including positive resection 
margins, nodal involvement and presence of satellite nodules. Patients with nodal 
metastases are at increased risk of recurrence following surgery, the remnant liver 
and lung being common sites for this. “Re-do” surgery may help prolong survival in 
these patients (Morise et al., 2010). Dissection in the region of the hepatoduodenal 
ligament provides a representative yield of lymph nodes and in addition to providing 





The capacity for these tumours to spread longitudinally beyond evident macroscopic 
margins has implications on surgical planning for resection. To enhance the 
prospects of a R0 resection, current recommendations favour a 10mm gross free 
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margin at the time of surgery in tumours with infiltrating morphology whereas 20mm 
is advocated for those with mass forming or intraductal phenotype (Akamatsu et al., 
2011). There is however conflict in the literature regarding the value of intra-
operative frozen section analysis to assess resection margins with extra-hepatic 
CCA due to both poor sensitivity (Endo et al., 2008) and the questionable effect of 
positive margins on overall survival in this scenario (Hernandez et al., 2008; Shingu 
et al., 2010). Lymphadenectomy in the region of the hepatoduodenal ligament is 
advisable (as for IH-CCA) as it provides prognostic information and possibly some 
survival advantage. Extended nodal retrieval beyond this basin is not 
recommended, as it does not add to survival (Aljiffry et al., 2009; Akamatsu et al., 
2011). 
 
1.1.7.1.3 Perihilar CCA 
 
Radial extension of perihilar tumours leads to invasion of liver parenchyma and 
structures within the hepatoduodenal ligament (portal vein & hepatic artery). Hepatic 
involvement necessitates liver resection, which in most circumstances implies an 
en-bloc caudate (segment 1) lobectomy (Agrawal and Belghiti, 2011). Extended 
right or left hemihepatectomy with removal of the affected extra-hepatic bile ducts is 
currently a standard for these tumours (Akamatsu et al., 2011). The laterality of 
resection is determined primarily by tumour location but also by technical ease. 
Right-sided resections are well suited for even central tumours and enable easier 
reconstructions of the remnant portal vein and biliary system (Agrawal and Belghiti, 
2011; Akamatsu et al., 2011). Central (meso) hepatectomy (removal of segments 
4a, 4b, 5 and 8) provides an alternative to extended resections, and lessens the risk 
of postoperative liver failure although technically is more demanding. Variations 
exist in this theme such as the ‘Taj Mahal’ resection, which utilises a dome shaped 
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incision to remove segments 1, 4a and 5 whilst allowing for relatively easier biliary 
reconstruction (Kawarada et al., 1999). Vessel involvement within the 
hepatoduodenal ligament can be managed with resection and reconstruction, 
though the impact of this on overall survival is currently unclear (Agrawal and 
Belghiti, 2011). Survival statistics indicate that hepatectomy and bile duct excision 
for hilar CCA provides 20-42% survival at 5 years (Akamatsu et al., 2011). 
Detrimental prognostic factors include increasing depth of tumour invasion into bile 
duct wall, poorer tumour differentiation (de Jong et al., 2011a) and nodal 
involvement. 
  
1.1.7.1.4 Distal EH-CCA 
 
Obtaining negative surgical margins usually implies resorting to Whipple’s resection/ 
pancreaticoduodenectomy for distal CCA, as opposed to segmental bile duct 
excision alone. Five-year survival following pancreatoduodenectomy in this situation 




The results of orthotopic liver transplantation (OLT) in CCA has improved with the 
institution of dedicated protocols in well-selected patients (De Vreede et al., 2000).  
Historically associated with discouraging results due to early tumour recurrence in 
up to 80% of patients (Petrowsky and Hong, 2009) and poor long-term survival of 
10-20% at 5 years (Aljiffry et al., 2009), OLT in CCA is currently the remit of 
specialised centres that can offer both appropriate neoadjuvant treatment and 
surgical expertise. Stage I/II intrahepatic and hilar CCA that are not resectable 
would normally be considered candidates for OLT in this setting. Patients with early 
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stage CCA on a background of PSC with risk of multi-focal tumours lend further 
support to transplantation (Grossman and Millis, 2010). Local criteria precluding 
resectability are bilobar disease, bilateral hepatic artery/portal venous involvement, 
suboptimal future liver remnant (with poor response to pre-operative portal vein 
embolization) and additionally in the case of hilar tumours, unilobar disease with 
involvement of contralateral vasculature (Petrowsky and Hong, 2009). Factors such 
as peritoneal disease, regional nodal involvement and distant metastases rule out 
OLT. Appropriate neoadjuvant options include external beam radiation, 
chemotherapy and intraluminal brachytherapy (Grossman and Millis, 2010). With 
the institution of such regimes in carefully selected patients, survival rates of 80% at 
5 years are achievable (Aljiffry et al., 2009; Grossman and Millis, 2010). The 
prognosis for incidentally detected CCA on explants following OLT for other 
indications is variable, with a focus on reducing the intensity of immunosuppression 
vital to reduce the risk of recurrence (Petrowsky and Hong, 2009). 
 
1.1.7.3 Adjuvant treatment 
 
 
There is currently no convincing evidence to suggest adjuvant therapy (using 
chemotherapeutic agents, radiation or both) has an effect on improving survival 




External beam radiation has variable results after resection of CCA, though at 
present it is thought to be more beneficial in those who have microscopic remnant 
disease after surgery. A contemporary meta-analysis of relevant observational 
studies has revealed an overall survival pooled hazard ratio of 0.62 (95% CI 0.48–
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0.78) in favour of adjuvant radiation versus observation alone in EH-CCA, 
suggesting that these patients would benefit from the former (Bonet Beltran et al., 
2011). Most subjects in this group however had positive resection margins and/or 
lymph node metastases. In IH-CCA, data from a large retrospective series has 
suggested that overall survival is significantly improved with the institution of post-
operative radiation, although information regarding resection margins was not 




Improved survival outcomes at 5 years have been reported from retrospective data 
following administration of intravenous gemcitabine and S-1 (an oral 
fluoropyrimidine) chemotherapy when compared to observation alone following 
resection of extra-hepatic biliary carcinomas (Murakami et al., 2009). In contrast, a 
prospective randomized trial examining a regime consisting of mitomycin C and 5-
fluorouracil showed no significant survival benefit for these agents following surgery 
for patients with bile duct cancer, although it did prove useful to those with gall 
bladder carcinoma (Takada et al., 2002). Both these studies did not segregate 
patients for chemotherapy based on surgical margins or nodal status. The impact of 
capecitabine after attempted curative resection of biliary tract cancer is being 
analysed in a randomized, prospective fashion in the United Kingdom currently 








Not surprisingly, there is lack of rigorous evidence to support the use of adjuvant 
chemoradiation following resection of CCA. Retrospective data on small numbers 
(n=34) supported the use of concurrent 5-fluorouracil therapy and radiation in the 
adjuvant setting following pancreatoduodenectomy for distal bile duct cancers 
(Hughes et al., 2007). The improved survival in this study was seen in comparison 
to historical controls and was present irrespective of nodal status. Older statistics 
have also indicated better survival following adjuvant chemoradiation compared to 
observation alone in patients with CCA (n=92), achieving statistical significance in 




Surgery remains the only means for cure in CCA and in the absence of the former, 
treatment is essentially palliative. Though options for palliation are many, the choice 
of optimal therapy remains frequently centre specific due to the sparse level-1 




The effect of brachytherapy (using 192Ir) in the palliation of CCA has been 
addressed in studies albeit mostly with smaller sample sets and in conjunction with 
external beam radiation. The value of brachytherapy alone in extending survival is 
questionable with data to show both benefit and lack thereof (Chen et al., 2004; 
Shinohara et al., 2010). It is however thought to extend the patency of biliary metal 
stents by preventing tumour ingrowth. Newer modalities such as radioembolization 
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utilising Yttrium-90 microspheres are currently gaining credence in the palliative 
treatment of IH-CCA, with possible improvement in life expectancy (Ibrahim et al., 
2008; Hoffmann et al., 2011). Taking into account all modalities of radiation 
treatment, there appears to be some survival benefit to its use in advanced or 
unresectable CCA, with studies noting an improvement in median survival from 4 
months in the absence of any treatment to 9-11 months with radiation alone 
(Shinohara et al., 2009; Shinohara et al., 2010). The risk for potential local toxicity 
including cholangitis, duodenal stenosis, bowel obstruction and gastrointestinal 




Palliative chemotherapy now has an established role in advanced CCA, 
combination treatment with Cisplatin and Gemcitabine offering good response rates 
and tumour control (Eckel and Schmid, 2007). Multi-centre phase-3 prospective 
randomized data from the contemporary Advanced Biliary Cancer (ABC)-02 trial 
has revealed improved progress free survival and an overall survival advantage (8 
months vs. 5 months) to patients receiving combination therapy with these same 
agents in comparison to monotherapy with Gemcitabine (Valle et al., 2010). More 
recently there has been phase-2 trial data to highlight the potential for targeted 
treatments in advanced CCA. The incorporation of Bevacizumab (a monoclonal 
antibody against Vascular Endothelial Growth Factor [VEGF]-A) into a regime 
containing Gemcitabine and Oxaliplatin (GEMOX) showed the combination to have 
an acceptable side effect profile whilst showing stable or improved tumour burden 
(as evidenced on combined Positron Emission Tomography-CT imaging) in 69% of 
the tested patient cohort (Zhu et al., 2010).  In another phase-2 study, the epidermal 
growth factor receptor inhibitor Cetuximab was similarly combined with GEMOX to 
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give good response in 63% of the tested group. Notably 30% of this cohort 
subsequently had potentially curative surgery in light of their response to treatment 
(Gruenberger et al., 2010). 
 
1.2 Targeted Diagnostics and Drug Delivery in Solid Cancers 
 
 
Since the advent of Nitrogen mustards following the 2nd World War as a primary 
systemic treatment for lymphomas, much progress has been made into the therapy 
and control of various cancers  (DeVita and Chu, 2008). Adjuvant chemotherapeutic 
regimens came in to the fore with breast cancers in the 1970s before this concept 
was expanded to the treatment of other solid malignancies. The realization that 
systemic chemotherapeutic agents exert their effects on non-cancerous normal 
tissue with consequent side effects has been a significant factor driving research 
into identifying targeted strategies. Such an approach also offers the possibility of 
specific and enhanced treatment delivery to target tissue thus improving therapeutic 
efficacy. 
 
The discovery of signalling pathways involved in both carcinogenesis and normal 
cellular activity were made through the efforts of the Special Virus Cancer Program 
in the 1970s and its subsequent incarnation as the Program of Molecular Biology. 
This laid the foundations for targeted molecular therapies (Morrison, 2010). 
Monoclonal antibodies were produced in the 1990s with the anti-CD20 antibody 
Rituximab proving to be the first such therapeutic antibody approved for the 
treatment of cancer, specifically lymphoma (Vacchelli et al., 2014). Another early 
example of the efforts into targeted cancer treatment was the drug Imatinib 
mesylate, a tyrosine kinase inhibitor used in the treatment of Chronic myelogenous 
leukemia (DeVita and Chu, 2008).  
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There has been recent focus on increasing the specificity of management 
approaches to solid cancers including CCA in order to increase diagnostic accuracy 
and treatment efficacy whilst minimizing side effects.  The two main avenues of 
research in this respect are related to targeted drug delivery and development of 
targeted signalling pathway inhibitors. 
 
 
The premise that tumour blood vessels are unique to and differ from their normal 
counterparts has stimulated much research into this field with a view towards 
preferentially targeting the former. Tumour tissue is additionally the seat of 
accelerated angiogenesis with the formation of new vessels that aid tumour growth 
and invasion. A variety of molecules have accordingly been devised (Klotz et al., 
2012), some of which have reached human trials/clinical application as summarized 
in  






























Colorectal, Renal & 
Hepatocellular cancers 
TRC105 IgG1 monoclonal 
antibody 
CD105 







Phase II/III trials in recurrent 
ovarian cancer 
Sorafenib 













Pazopanib Renal Cell Carcinoma 
 
Table 5: Angiogenic inhibitors in clinical use 
VEGFR- Vascular Endothelial Growth Factor Receptor, PDGFR- Platelet Derived Growth 
Factor Receptor. 








Figure 9: An overview of membrane receptors mediating angiogenesis and their 
inhibitors 
Depiction of VEGF and non-VEGF mediated angiogenic membrane receptors, their ligands 
(circles) with drugs that can block their actions (rectangles). VEGF(R)- Vascular Endothelial 
Growth Factor (Receptor), PDGF(R)- Platelet Derived Growth Factor(Receptor), FGF(R)- 
Fibroblast Growth Factor(Receptor), Ang- Angiopoietin, TGF(R)- Transforming Growth 
Factor (Receptor),NP- Neuropillin, ALK- Activin Receptor-like Kinase. 
(From Clarke JM and Hurwitz HI. Understanding and targeting resistance to anti-angiogenic 
therapies. J Gastrointest Oncol. 2013; 4: 253–263.  DOI: 10.3978/j.issn.2078-






CD31 is a 130kDa transmembrane glycoprotein receptor, also termed Platelet 
Endothelial Cell Adhesion Molecule (PECAM)-1 is ubiquitous to vascular 
endothelium where it is a component of endothelial intercellular junctions. The 
molecule is therefore considered more of a vascular marker and provides an index 
of angiogenesis, rather than a target. It is also present on the surface of non-
erythroid haemopoietic cells such as macrophages, monocytes, platelets and 
neutrophils.  CD31 is believed to play a vital part in the maintenance of normal 
vascular integrity, whereas during the inflammatory cascade it promotes leucocyte 
migration from the circulation into tissues. Separate to these functions, CD31 has 
also been shown to serve a crucial role in angiogenesis by hastening endothelial 
cell migration, intercellular junctional development and capillary formation. Its 
abilities to prevent platelet activation and stimulate vessel prostacyclin production 
further aid in its regulatory role in vascular homeostasis (Privratsky and Newman, 
2014). 
In immunohistochemistry (IHC) studies, CD31 has earned its reputation as a pan-
endothelial marker and is frequently used as the reference standard or denominator 
(along with markers such as CD34) against which other angiogenic markers are 
assessed in tumour tissue.  It is not without its drawbacks nonetheless (Nico et al., 
2008). As indicated above, it is not specific for vascular endothelium, and shows 
affinity for peri-vascular stromal tissue. The distribution pattern of CD31 within 
normal liver tissue shows it to be in abundance, with hepatic sinusoids, centrilobular 
veins, portal venules and arterioles all showing strong positivity to the marker 
(Pusztaszeri et al., 2006). Additionally, the marker is not able to distinguish between 
proliferating and mature endothelium (Nico et al., 2008). 
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The prognostic impact of CD31 expression in cholangiocarcinoma has been 
examined in some detail in prior publications. Thelen and associates assessed 
CD31 microvessel density (MVD) in 60 cases of resected PH-CCA and divided 
patients into 2 groups based on a seemingly arbitrary MVD cut-off value of 20. They 
found a higher incidence of nodal metastases and local recurrence in those tumours 
with a higher MVD, which also translated into a significantly poorer overall survival 
(OS) and disease-free survival (DFS) in this cohort (Thelen et al., 2008). The same 
authors in a subsequent paper examined CD31 expression in 114 cases of intra-
hepatic CCA and following stratification of patients based on a mean MVD value of 
12.6, found higher T stage tumours, R1 (positive margin) resection rates and 
recurrence in those with higher MVD. Interestingly, in this scenario high MVD had 
no bearing on nodal metastases, though it retained an independent adverse 
prognostic effect on OS (Thelen et al., 2010). 
 
1.2.2 Vascular Endothelial Growth Factor Receptor-2 
 
 
VEGF is integral to vessel development in both normal and tumour tissue. The 
VEGF family consists of A, B, C and D subtypes of which VEGF-A is considered to 
be the rate-limiting factor in angiogenesis whereas VEGF-C & D are involved in 
lymphangiogenesis (Ferrara et al., 2004). VEGF-A is expressed by endothelial cells 
and tumour tissue but is also secreted and bound to the extracellular matrix in 
significant amounts. The actions of this molecule are exerted through 3 of its 
tyrosine kinase receptors (VEGFR1, 2 and 3). Vascular Endothelial Growth Factor 
Receptor-2  (VEGFR2) is thought to be more relevant to the angiogenic and 
mitogenic actions of VEGF-A though not exclusive to it. VEGFR3 mediates the 
actions of VEGF-C and D on lymphatic endothelium.  
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Current evidence supports the fact that VEGFR2 & 3 are overexpressed on tumour 
endothelium of various solid cancers, compared to corresponding normal tissue 
(Smith et al., 2010). In EH- and IH-CCA, studies have shown VEGF-A expression to 
be increased though not to any prognostic level (Tang et al., 2006; Mobius et al., 
2007). Nonetheless, as discussed earlier,  when combined with standard 
chemotherapeutic agents in the treatment of advanced biliary cancer in a phase-II 
trial, the monoclonal antibody to VEGF Bevacizumab has shown some degree of 




CD105 (Endoglin) is a 180kDa transmembrane glycoprotein receptor present mostly 
in vascular endothelium, and to a lesser degree in vascular smooth muscle/stroma, 
tissue macrophages and erythroid precursors (Fonsatti and Maio, 2004). The 
molecule forms part of the cell surface receptor complex to Transforming Growth 
Factor (TGF) - β1 and β3, where it modulates signalling of the latter. CD105 is 
induced in hypoxic conditions, and counteracts the anti-angiogenic actions of TGF- 
β1. Thus in the relatively ischaemic confines of tumour tissue, CD105 is understood 
to play a vital role in promoting angiogenesis (Duff et al., 2003). The mechanisms 
accounting for its actions on vasculature are in part due to the positive modulatory 
effects of CD105 on endothelial Nitric Oxide synthase and Cyclooxygenase-2 
expression (Dallas et al., 2008; Fonsatti et al., 2010).  CD105 is also believed to 
possess cellular functions independent of its actions via the TGF-β1 pathway, 
including protection of endothelial cells against apoptosis under hypoxic stress 
conditions (Fonsatti and Maio, 2004). 
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In contrast to pan-endothelial markers such as CD31 and CD34, CD105 is thought 
to be specific for immature or proliferating (“activated”) endothelium (Dallas et al., 
2008; Fonsatti et al., 2010). Accordingly, the marker has been purported to be the 
most specific for tumour vasculature, though this view is not entirely accurate as 
indicated above.  
Discrepant staining patterns of various CD105 monoclonal antibodies on both 
normal and tumour tissue have been noted in the literature, and have been 
attributed to the several distinctive epitopes of the receptor that react to different 
monoclonal antibodies (Duff et al., 2003; Fonsatti et al., 2010). This finding bears 
relevance when designing a relevant theragnostic model as all relevant epitopes 
must be tested to strike an optimal balance between adequate tumour targeting and 
minimal off-target effects on normal tissues (Fonsatti and Maio, 2004).  
There is an abundance of literature looking into the expression of CD105 in various 
solid cancers including adenocarcinomas of the upper digestive tract, colon, breast 
and prostate, and most show an association between higher tumoral CD105 MVD 
and metastasis and poorer OS (Dallas et al., 2008). In terms of hepatic malignancy 
a few reports have delved into CD105 expression in hepatocellular carcinoma but 
none into CCA. Yang et al from China examined the impact of CD105 expression in 
113 HCC specimens utilising the SN6h clone of mAb. It was found that there was 
absent expression of the marker in all non-tumourous tissue and CD105 carried a 
prognostic impact on OS (Yang et al., 2006). Predating this was a report by Ho and 
colleagues who scrutinised the expression pattern of CD105 in 86 cases of resected 
HCCs and found disparate results. A lower CD105 MVD score correlated with larger 
tumour size (>5cms), higher tumour stage and tumours with venous invasion. No 
prognostic effect was noted with tumoural CD105 expression on this occasion and 
the authors also noted a diffuse CD105 staining pattern in peri-tumoural liver tissue 
(in 23% of cases) that was associated with increased risk of recurrence. Though the 
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reasons for this phenomenon were not clear, it was noted that HCCs develop on the 
background of chronic liver disease and cirrhosis, where angiogenesis is expected 
to be active (Ho et al., 2005). This latter observation was confirmed in a separate 
study that analysed CD105 expression in 3 distinct areas of 64 resected HCC 
specimens (tumour tissue, peri-tumoural and distant liver >5cms away) as well as 
normal non-diseased liver controls. These authors showed diffuse CD105 positivity 
in hepatic sinusoidal cells of the peri-tumoural and distant liver groups but not so in 
normal controls, where expression was seen only in hepatic sinusoidal cells 
adjacent to portal tracts. CD105 protein was in fact found to be significantly 
increased in peri-tumoural and distant liver compared to tumour tissue, and it was 
therefore opined that in the presence of background liver disease such as cirrhosis, 
anti-angiogenic therapy using CD105-based approaches may not be beneficial due 
to off-target effects.  The observation of increased CD105 expression in peri-
tumoural tissue has also been noted elsewhere, in this instance both in the case of 
HCCs and liver metastases (Nakamura, 2009), and the injury and regeneration of 
hepatocytes in this region is believed to be the cause. These findings were mirrored 
in more recent papers that have shown CD105 expression to progressively 
decrease from regenerative nodules through dysplastic nodules to small HCCs 
(Paschoal et al., 2014; Segatelli et al., 2014). 
The feasibility of a tumour imaging platform utilising CD105 has been long 
established in various pre-clinical studies. In one of the first such reports dating 
back to 2000, one group showed that intravenously administered radiolabelled 
CD105 antibody highlighted spontaneous mammary cancers in 2 canine subjects, 
with no adverse effects related to the agent during 3 months of follow up (Fonsatti et 
al., 2000). In a similar study, Bredow and associates utilized a radiolabelled 
monoclonal antibody to CD105 to demonstrate tumour localization in a mouse 
model of melanoma (Bredow et al., 2000). More recently, the use of a CD105-based 
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MB tumour imaging system to monitor response to treatment was described by 
Korpanty and colleagues (Korpanty et al., 2007). They used MBs coated with 
antibody to CD105 to demonstrate diminished tumour vascularity (as evidenced by 
lower video intensity on US) as a result of Gemcitabine treatment in a pancreatic 
murine xenograft model. These findings were confirmed by lower MVD scores in 
harvested xenograft tissue. 
In terms of clinical translation, the results of human Phase 1 trials using the 
monoclonal CD105 antibody TRC105 have been reported recently (Rosen et al., 
2012). Fifty patients with various types of advanced solid malignancy not amenable 
to any curative therapy were recruited into the study, and further to treatment 
improved or stable disease was observed in 47% of subjects. Notable side effects 
of therapy included hypo-proliferative anaemia and cutaneous telangiectasia. 
Overall, grade 3 adverse reactions were seen in 3 patients. 
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1.3 Applications of Tumour Targeted Treatments and the 




The development of nanoscale particles and the physical and biological attributes of 
these molecules in vivo have allowed the investigation of new approaches to the 




Microbubbles (MBs) are micron-sized (2-5µm) encapsulated gas bubbles 
comprising an outer stabilizing shell and an inner gaseous core (Deshpande et al., 
2010). The inherent ability of MBs to remain confined to the circulation after 
systemic injection (due to their size) coupled with their acoustic reflectivity render 
them useful as intra-vascular ultrasound contrast agents. Additionally, the 
physicochemical properties of MBs allow them to maintain their physical integrity 
within the circulation yet they exhibit structural instability and leakage when exposed 
to a suitable trigger. This property of MBs is harnessed in targeted applications 
where they are coated with various payloads (such as drugs) on their surface. 
These payloads can then be released into tumour specific circulation upon the 
topical application of a MB-destructive regional ultrasonic pulse to the area of 
tumour. Thus MBs have the potential to simultaneously aid in diagnosis and 





Methods of MB production involve processes such as mechanical agitation, 
agitation utilising ultrasound frequencies (sonication) or the use of microfluidic 
devices (Kiessling et al., 2012; Peyman et al., 2012). MB shells are made of varying 
materials including  albumin, polymers or phospholipids, whereas the gaseous 
centre consists typically of a mixture of high molecular weight inert gases (such as 
perfluorocarbon [PFC] or sulphur hexafluoride) and air (Deshpande et al., 2010).  
This gas mixture at the core of MBs confers them with their unique ultrasound 
characteristics and provides them with physical stability in vivo. The use of too high 
a concentration of air leads to MB collapse due to diffusion of nitrogen away from its 
core, whereas an excess of inert gas promotes core liquefaction leading to 
shrinkage (Ibsen et al., 2013). However, nanoscale dimension MBs (less than 1.5 
µm size, termed micro/nanobubbles) are also being developed and can carry 
molecules such as oxygen beyond most capillary beds directly into tissue (Matsuki 
et al., 2014).  
 
The circulatory half-life of conventional unbound MBs is to the order of 3-15 
minutes. This period can be prolonged by instituting measures such as coating the 
MB shell with polyethylene glycol (PEG), which prevents the bubbles from 
coalescing within the circulation (steric protection). Enhancing circulatory time in this 
fashion allows more passes of MBs through tumour vasculature and augments the 
potential for these agents to exert more therapeutic effect. MB clearance is effected 
by the reticulo-endothelial system viz. the liver and spleen (Ibsen et al., 2013). A 
relevant concern in this regard is the potential for off-target effects once unused 
MBs are degraded and metabolised in these organs. 
 
Cellular targeting using MBs can involve 2 distinct processes. Passive targeting 
makes use of MB shell properties to help localize them to cells or tissues of interest 
eg. albumin shells attract the binding of leucocytes (Kiessling et al., 2012) and can 
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help them localize to areas of inflammation. Alternatively, active targeting refers to 
the use of specific targeting ligands (to vascular endothelium) attached to the MB 
shell through covalent or non-covalent means. The diagnostic capabilities of MBs 
arise from their acoustic reflectivity under ultrasound (US) insonation once they are 
bound to specific antigens in the area of interest through the use of targeting 
ligands. On the other hand, the therapeutic potential afforded by MBs stems from 
the physiological effects of ultrasonic waves on MBs.  At the high acoustic 
pressures (mechanical index >0.4) created by ultrasound, circulating MBs in the 
field begin to oscillate and ultimately burst or implode, causing cavitation and micro-
jet formation (Figure 10). These processes release any attached payload from MBs 
into the immediate vicinity. In addition, these processes and the resulting fluid 
microstreaming in the surrounding blood leads to transient changes in vascular 
endothelium and cell membranes, a phenomenon termed sonoporation.  Vascular 
and cell permeability is increased through sonoporation driving MB payloads 
intracellularly, where they can exert their effects (Smith et al., 2011; Ibsen et al., 
2013) as shown in Figure 11. 
 
Enabling MBs with targeting capability involves attaching specific vascular ligands 
to their shells. This process traditionally involves utilising linker molecules such 
(Strept)Avidin (on the MB shell) and Biotin (on the antibody). Avidin is a protein 
ubiquitous in egg white whilst its bacterial equivalent Streptavidin is found in 
Streptomyces avidinii. Both these proteins carry 4 binding sites per molecule for 
Biotin (Vitamin B7) and this non-covalent interaction is characterised by its high 
degree of stability and strength (Diamandis and Christopoulos, 1991), rendering 














































Figure 10: Effects of therapeutic ultrasound (US) application 
to intravascular microbubbles (MBs) 
Panel A showing the shrinkage and expansion of MBs during the 
compression an rarefaction phases respectively of an incoming 
US wave. Panel B- Fluid streamlines are produced around MBs 
due to changes in MB diameter when exposed to US, which aid 
in sonoporation. Panel C displays the direct consequences of MB 
lysis under the effects of US.  
Taken from Ibsen et al. Microbubble-mediated ultrasound 
therapy: a review of its potential in cancer treatment. Drug Des 
Devel Ther. 2013; 7: 375–388. doi: 10.2147/DDDT.S31564. Used 
under the Creative Commons Attribution - Non Commercial 









Figure 11: Payload delivery using microbubbles 
Upper panel showing various  possible payloads for MBs. Lower panel illustrating how 
payloads can be driven into target tissue under the influence of therapeutic mode US. 
Modified from Turánek et al. Lipid-Based Nanoparticles and Microbubbles – 
Multifunctional Lipid-Based Biocompatible Particles for in vivo Imaging and 
Theranostics. In Advances in Bioengineering 2015, Serra P (Ed), InTech, DOI: 






Figure 12: Microbubble structure with targeting ligands and 
payloads 
Diagram of a targeted lipid shell MB showing the utility of 
avidin-biotin linkages in aiding the attachment of theragnostic 
payloads such as drug containing liposomes or antibodies. 
Taken from Peyman et al. Expanding 3D geometry for 
enhanced on-chip microbubble production and single step 
formation of liposome modified microbubbles. Lab Chip, 
2012;12: 4544-4552 DOI: 10.1039/C2LC40634A. Reproduced 
with permission from the publisher. 
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its disadvantages though, and the main drawback of this system is the inherent 
immunogenicity of (Strept)avidin in humans, which limits its in vivo use. Alternative 
bio-conjugation strategies have been explored as a result and show promise, 
including maleimide-thiol conjugation (Yeh et al., 2015). 
 
Conventional MBs are largely well tolerated in their current clinical applications 
though reported side effects include hypersensitivity, allergic reactions, embolic 
events and microvascular damage (Kiessling et al., 2012). In terms of targeted 
applications, progress has been made into the clinical setting with a recently 
completed trial of VEGFR2 directed MBs (BR55) in patients with prostate cancer 
prior to surgery, although the results of this study are still pending. Histopathological 
and Immunohistochemical examination of resected specimens will reveal if pre-
operative imaging with BR55 bears correlation with areas of VEGFR2 expression in 
tumours (Willmann). 
 
1.3.2 Nanoparticles and Nanomedicine 
 
Nanotechnology in the field of medicine refers to the use of biological materials in 
the nanoscale dimension i.e. typically <100nm size. Within the scope of cancer 
therapeutics, nanotechnology is an attractive proposition on account of the 
Enhanced Permeability and Retention (EPR) effect exhibited by tumour 
endothelium. This endothelium is often aberrant and leaky with gaps between cells 
ranging several hundred nanometers (Wang et al., 2012). In addition, tumour 
lymphatics are frequently defective leading to impaired clearance of substances 
from the interstitium. These 2 phenomena allow nanoparticles (NPs) to selectively 
accumulate within tumour tissue (passive targeting) when compared to other 
macromolecules. However, only around 5% of a total administered dose localises to 
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tumour in this fashion (Bae and Park, 2011). In contrast, active targeting of NPs 
refers to ligand-mediated selectivity and enables an added level of homing in of 
payloads to target tissue. NPs can be coated with a target specific ligand that 
imparts additional targeting capacity to these molecules. Ligands used in this 
fashion include transferrin, folate and tumour necrosis factor-α (Galvin et al., 2012). 
Various forms of NPs exist including liposomes, polymerosomes, metal 
nanoparticles, dendrimers and quantum dots (Galvin et al., 2012) as shown in Table 
6. Liposomes were one of the first NPs to reach clinical application and consist of 
an aqueous core encapsulated by a shell. The latter is typically composed of lipid 
and is arranged into a bi-layered membrane. This configuration allows liposomes to 
carry hydrophilic molecules within its core, or hydrophobic materials within its shell. 
The fact that liposomes are easily biodegraded make them particularly useful, which 
is in contrast to metal NPs that can accumulate in vivo, leading to concerns 
regarding toxicity (Wang et al., 2012). 
 
Nanoparticles are metabolised in a similar fashion to MBs via the Reticulo-
endothelial system, and Kupffer cells within the liver and splenic macrophages play 
a significant role in effecting this. As for MBs, modifying NPs with processes such 
as PEGylation serve to enhance their circulatory half-life by masking their surface 
charge and helping decrease the rate of opsonisation and phagocytosis of these 
materials by Immune cells. Nonetheless, by virtue of their size, NPs can pass not 
only through endothelium that is deficient/leaky (as is observed in the tumour milieu) 
but also through fenestrated endothelium which is native to liver, spleen and bone 
marrow. Thus some accumulation in these organs is unavoidable (Duskey and 
Rice, 2014). In fact, up to 95% of a systemically administered, standard NP dose is 
cleared by the Immune system within minutes, preventing adequate tumour 







Name Size (nm) Characteristics 
Liposomes 50-100 
Bilayered , phospholipid vesicles with 
hydrophilic core & hydrophobic 
lamellae 
Dendrimers <10 
Branching, radially symmetric 
macromolecules composed of amino 
acids, sugars or nucleotides 
Metal nanoparticles 10-20 
Composed of biocompatible, inert (eg. 
Gold) or magnetic (Iron) metals but 
prone to accumulation in vivo 
Quantum Dots 10-15  
Fluorescent semiconductor materials 
able to link biological molecules  
Polymeric nanoparticles 
<100 
Self assembling, bio-degradable 
polymers with hydrophobic core and 
hydrophilic shell 
Table 6: Nanoparticles commonly used in biomedical research applications 






The ground realities with the efficacy and kinetics of NP usage in humans are 
somewhat different to those expected with active and passive targeting 
mechanisms alone (Figure 13). There is evidence that systemic NPs interact with 
plasma proteins soon after intravenous injection and this leads to the formation of a 
‘corona’ that masks targeting ligands on the NP surface. This aids off-target cellular 
binding and increases net NP molecular weight which impedes EPR (Lazarovits et 
al., 2015).  
 
1.4 The search for theragnostic biomarkers in 
Cholangiocarcinoma 
 
With the lack of consistent, specific biomarkers in CCA, the ability to target these 
tumours at a molecular level to facilitate diagnosis or therapeutic delivery is 
currently inadequate. Bile may contain more valid CCA biomarkers than serum 
(though the latter is more easily collected) since bile is a ‘proximal’ fluid to such 
tumours and literally bathes the surfaces of these malignant cells. Farid and 
colleagues undertook proteomic analysis of bile in 4 patients with peri-hilar CCA 
with a view towards identifying potential biomarker candidates (Farid et al., 2011). 
Through this work, the group was able to identify various proteins that were over- 
expressed in the bile secretome. Of these, Matrix metalloproteinase- 9 (MMP9) and 
Neutrophil Gelatinase- Associated Lipocalin (NGAL) were found to be preferentially 
expressed (Farid, 2014). Given the potential of these 2 proteins as CCA 
biomarkers, they were subsequently taken forward to explore their applicability as 




Figure 13: Expected versus actual nanoparticle interactions with target 
tissues 
Illustration of the expected in vivo effects of nanoparticles on target tissues 
(Panels A and B) versus the observed effects (Panels C and D). The interaction 
of NPs with plasma proteins leads to diminished active and passive targeting, with 
the promotion of off-target side effects. Taken from Lazarovits et al. Nanoparticle–
blood interactions: the implications on solid tumour targeting. Chem. Commun  
2015; 51: 2756-2767; DOI: 10.1039/C4CC07644C. Reproduced with permission 
from the publisher 
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The exact roles played by NGAL and MMP9 in the progression of solid cancers are 
yet to be fully elucidated. It is understood that NGAL exerts antimicrobial effects in 
vivo which are closely linked to its function as an iron chelator and these are 
mediated through the NGAL cell surface receptor 24p3R. Intracellular iron depletion 
is also known to induce apoptosis and may be one of the mechanisms by which 
NGAL induces cancer cell death (Devireddy et al., 2005). Other pathways by which 
NGAL may exert anti-cancer effects is through the inhibition of VEGF synthesis via 
the down-regulation of Hypoxia inducible factor-1alpha and by the inhibition of Focal 
Adhesion Kinase phosphorylation (Candido et al., 2015). Somewhat paradoxically, 
NGAL also functions as a MMP9 stabilizer in the extra-cellular matrix which helps 
promote tumour invasiveness and metastatic capability in certain cancers by virtue 
of MMP9’s gelatinase activity (Chakraborty et al., 2012).  
 
1.4.1 Neutrophil Gelatinase-Associated Lipocalin 
 
 
Neutrophil Gelatinase-Associated Lipocalin (NGAL/Uterocalin/Siderocalin/oncogene 
24p3/Lipocalin-2) is a 198 amino acid long glycoprotein that is a member of a group 
of secreted transport proteins termed lipocalins. These proteins are afforded 
specific ligand binding properties by virtue of a common tertiary protein structure 
termed the ‘lipocalin fold’ which renders them capable of  transporting lipophilic 
substances (Chakraborty et al., 2012). NGAL has in recent years attracted 
increasing interest as a marker of homeostatic dysregulation since serum and tissue 
concentrations of this protein are frequently deranged in acute inflammation and 
neoplasia. Initially discovered as a complex with the 92kDa Type-IV gelatinase (i.e. 
MMP9) within human neutrophils (thus lending it its name), this covalently linked 
135 kDa complex was found not to be the main form of the NGAL protein, but rather 
as a freestanding 25kDa peptide.  (Kjeldsen et al., 1993). The NGAL gene is 
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located on chromosome 9q and the NGAL protein is exocytosed mostly in a free 
form from late granules of neutrophils. Subsequent work has shown that various 
tissues normally express NGAL including the bronchus, sections of the 
gastrointestinal tract, kidneys, breast, colon and prostate (Friedl et al., 1999; 
Chakraborty et al., 2012). A prime function of NGAL is believed to be the transport 
of iron intracellularly, which is achieved through a specific 24p3R (megalin) receptor 
(Bolignano et al., 2010), a phenomenon that helps prevent apoptosis in these cells 
(Devireddy et al., 2005). The molecule is understood to aid in innate immunity by 
both depleting bacteria of iron thus causing their death and promoting neutrophil 
chemotaxis. This ties-in with its behaviour as an acute phase protein with increased 
serum levels of NGAL seen following a stress event. 
 
Within the spectrum of benign pathology, NGAL expression is understood to be up-
regulated in several inflammatory disorders such as psoriasis, chronic eczema, 
myocarditis, and inflammatory bowel disease. Ischaemic conditions such as 
cerebral and myocardial infarction and acute kidney injury also lead to a rise in local 
NGAL whereas metabolic diseases leading to raised levels of the protein include 
Diabetes Mellitus and obesity (Chakraborty et al., 2012).  
 
NGAL also plays an important role in promoting cancer growth that is believed to be 
mainly via the positive modulatory and stabilizing effects it has on MMP9 
extracellularly, though other mechanisms independent of MMP9 may exist such as 
anti-apoptotic effects. There is data to support increased NGAL expression in 
malignancies of the breast, upper digestive tract and thyroid amongst others with 
positive correlation noted between it and tumour parameters such as differentiation 
and stage (Chakraborty et al., 2012) but paradoxically other studies have shown it 
may exert anti-neoplastic effects, viz. in pancreatic, ovarian and colonic cancers 
(Bolignano et al., 2010). These contradictions are perhaps not fully attributable to 
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technical aspects between studies such as differences in antibodies used, and may 
actually indicate a varying role for this marker amongst different cancers. 
Nonetheless, current evidence supports NGAL to be pro-neoplastic in CCA.  
 
The feasibility of utilising serum and biliary NGAL levels to differentiate CCA from 
benign conditions of the biliary tract has been explored in several reports, with 
conflicting results. Leelawat et al (Leelawat et al., 2011) analysed serum levels of 
NGAL and CA 19-9 in a group of 50 patients with CCA (of which 72% cases were 
PH-CCA) and observed that levels of both these biomarkers were significantly 
elevated in comparison to levels within a group of 50 patients with benign biliary 
tract disorders (stone disease and strictures). The area under curve (AUC)-receiver 
operating characteristic (ROC) was noted to be 0.79 for NGAL and 0.81 for CA 19-
9. It must be added that the degree of biliary obstruction (as evidenced by bilirubin 
levels) was significantly higher in the CCA group as well in this study. Significantly 
higher NGAL titres were also noted in those patients with advanced stage CCA 
when compared to early stage tumours. In a similar fashion, Budzynska and 
colleagues determined serum NGAL and CA 19-9 levels in a group of 40 patients 
with biliary obstruction (16 CCA, 6 pancreatic cancer and 18 benign strictures) but 
found no difference in NGAL levels between malignant and benign groups 
(Budzynska et al., 2013). However, they did also concurrently analyse biliary NGAL 
levels and found this to be significantly raised in the malignant cohort (AUC-ROC 
0.73), as were serum CA 19-9 levels (AUC-ROC 0.86). These findings mirror the 
results obtained through the earlier work of Zabron and co-workers (Zabron et al., 
2011) who further to upfront biliary proteomics work, determined biliary NGAL levels 
in an initial “discovery” cohort of 38 patients, 16 of which had malignant biliary 
obstruction (2 CCA cases). They noted statistically higher levels of biliary NGAL in 
malignant obstruction (AUC-ROC 0.76) and replicated these findings within a further 
“validation” cohort of 21 patients (7 malignant cases, no CCA).  Peak bilirubin levels 
 72 
in the malignant group were significantly higher than in their benign counterparts, in 
both discovery and validation cohorts.  
 
The tissue expression of NGAL in CCA and normal liver tissue has not been 
analysed in detail to date. Nuntagowat and co-workers whilst noting decreased in 
vitro invasiveness of the CCA cell line RMCCA-1 with siRNA-induced NGAL 
knockdown were unable to show any correlation between NGAL IHC expression 
and tumour differentiation, lymph nodal status or metastases in their cohort of 24 
CCA cases (Nuntagowat et al., 2010). Although it is unclear whether their tissue 
samples were taken from a homogenous group of one particular CCA subtype, they 
did observe NGAL expression in all their tumours with strong staining in 75% of 
cases, and no staining was seen in non-tumorous tissue. Friedl and associates in 
an older study assessed NGAL staining patterns in several normal tissues and 
found normal hepatocytes to be negative, whereas smaller intra-hepatic bile ducts 
showed focal positivity (Friedl et al., 1999). Nonetheless, under conditions of 
experimental liver injury or cholestasis, NGAL tissue expression and serum levels 
have been observed to be markedly increased, with injured hepatocytes being the 
source (Borkham-Kamphorst et al., 2011).  Despite the relative lack of data with 
NGAL in CCA, the former has been studied in better detail in other 
hepatopancreatobiliary malignancies. One report looked into the impact of NGAL in 
HCC, and through the use of HCC cell lines in in vitro and in vivo studies, this group 
was able to show that the proliferation, local invasiveness, and metastatic capability 
of HCC was dampened by NGAL (Wang et al., 2013). This was attributable to 
NGAL mediated suppression of Epithelial to Mesenchymal Transition via 
downregulation of Epidermal Growth Factor and Transforming Growth Factor -beta1 
(TGF-β1). Conversely, an earlier IHC study using 138 cases of HCC from curative 
resection samples showed significant up-regulation of NGAL and its receptor 
(NGALR) in those patients with features of vascular invasion and higher TNM stage. 
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Furthermore, Cox regression analysis identified NGAL and NGALR expression as 
independent predictors of poorer overall survival in HCC (Zhang et al., 2012). The 
expression profile of NGAL in pancreatic adenocarcinoma has been explored as 
well, with one IHC report noting 100% positivity in a sample cohort of 27 cases. An 
increasing stain intensity was seen with better tumour differentiation, along with a 
significantly lower degree of staining in normal pancreatic tissue (Moniaux et al., 
2008).  Similar results were arrived at in another report where significantly higher 
proportion (45%) of 73 pancreatic cancer tissue samples stained positive for NGAL 
when compared to 26% of 77 normal/chronic pancreatitis controls (Tong et al., 
2008). The data regarding NGAL expression in other solid cancers is disparate at 
best, with both pro- invasive and anti-cancer effects noted in cancers of the breast, 
oesophagus, stomach, and colon (Chakraborty et al., 2012; Candido et al., 2015). 
 
1.4.2 Matrix metalloproteinase-9 
 
Matrix metalloproteinases (MMPs) are a group of zinc dependent endopeptidases 
that play a pivotal role in normal tissue homeostasis, inflammation and tumour 
progression, of which there are currently 23 known members (Kessenbrock et al., 
2010). MMPs share a structure having three common domains in their amino acid 
sequence. The pro-peptide domain contains a cysteine residue that interacts with a 
zinc ion in the catalytic domain maintaining enzyme latency. MMPs are activated 
upon disruption of the cysteine-zinc interaction by means of a “cysteine switch”, 
which involves proteolysis of the pro-peptide domain. Various cells express these 
enzymes including neutrophils, lymphocytes and endothelial cells in addition to 
stromal elements such as macrophages and fibroblasts. Physiological inhibition of 
MMPs is achieved through tissue inhibitors of metalloproteinase (TIMP) of which 
there are currently 4 subtypes (Kessenbrock et al., 2010).  
 74 
Matrix metalloproteinase-9 (MMP9/92 kDa Gelatinase/92 kDa Type IV Collagenase) 
is secreted into the extra-cellular space as a latent 92kDa protein. It is subsequently 
cleaved to active 82 and 65kDa isoforms, which aid in digesting the extra-cellular 
matrix (Vempati et al., 2007). It is unique in its role in tumour progression and acts 
at various levels. In the setting of malignancy MMP9 can activate TGF-β signalling 
via the CD44 receptor in a deregulated manner leading to increased tumour 
invasiveness (Yu and Stamenkovic, 2000). Additionally in conjunction with MMP2 
and MMP14, MMP9 plays an important role in promoting tumour angiogenesis by 
increasing the local bioavailability of VEGF (Kessenbrock et al., 2010). 
 
There is data to suggest a role for MMP9 in the progression of CCA. Whilst serum 
levels of MMP9 have not reliably helped to differentiate benign from malignant 
biliary pathology (Leelawat et al., 2009), immunohistochemistry studies have shown 
divergent results. A preliminary report looked at the expression of various MMPs 
and TIMPs in normal liver tissue, IH-CCA and HCC (Terada et al., 1996). It noted a 
lack of MMPs and TIMPs in normal hepatocytes though marginal staining was 
observed in bile ducts. The degree of epithelial positivity of both sets of markers 
correlated with local invasiveness but not tumour differentiation, and a small degree 
of stromal expression was also seen. MMP9 expression in IH-CCA was detected in 
only 27% (3 out of 11) cases. A similar report from Japan analysed MMP9 
expression in 37 resected cases of intrahepatic CCA, and noted positivity in 43% of 
cases (Shirabe et al., 1999). Higher expression of MMP9 was significantly 
associated with the risk of nodal metastases and poorer overall survival, as well as 
nodal recurrence.  Another group analysed tissue expression of MMP9 in 42 cases 
of PH-CCA using reverse-transcriptase Polymerase Chain Reaction techniques and 
found it to be increased relative to normal liver tissue. No clinical data was however 
available in this study  (Li et al., 2005). Kirimlioglu and colleagues subsequently 
ascertained the expression of MMP9 amongst other MMPs in a heterogenous group 
 75 
of 44 biliary cancers, 8 of which were PH-CCA cases (Kirimlioglu et al., 2009). 
MMP9 was observed to be expressed in both normal hepatocytes and tumour 
epithelia in PH-CCA, and more so in cases with neural invasion. No particular 
correlation between staining intensity and any other clinicopathological variable was 
seen in this series. More recent work involving 58 patients who had curative 
resection of PH-CCA has also highlighted the lack of correlation of degree of MMP9 
expression with clinicopathological data although it was also shown that high 
expression of MMP9 and the presence of nodal metastases were independently  
associated with poorer overall survival (Sun et al., 2014). There is anecdotal 
evidence into the use of MMP9 inhibitors as palliative therapy in unresectable CCA, 
and a reduction in CA 19-9 levels was noted in 2 of the four patients offered this 
treatment with oral Marimastat (French et al., 2005). The median survival noted was 
22 months. Whilst MMP inhibitors such as Marimastat have thus far failed to reach 
effective clinical translation in solid cancers, this is in part attributed to their non-
specific nature leading to musculoskeletal toxicity and intolerance (Bramhall et al., 
2002; Fingleton, 2008).There is therefore scope to improve MMP therapeutics by 





1.5 Aims and Objectives 
1.5.1 Aims 
The aims of this project were to: 
1. Assess the prognostic relevance of NGAL and MMP9 expression in PH-
CCA and evaluate the validity and potential of these biomarkers in the 
future development of a targeted theragnostic system in CCA. 
2. Examine the expression of the vascular endothelial markers CD105 and 
VEGFR2 in PH-CCA and assess the efficacy of vascular endothelial 
targeting using in vitro and in vivo models. 
 
1.5.2 Objectives 
The objectives of this study were as follows: 
 
a) To investigate NGAL and MMP9 as biomarkers in PH-CCA using IHC on 
archival formalin-fixed paraffin embedded (FFPE) tissue, and to relate their 
tissue expression to clinicopathological outcomes. 
b) To assess a panel of CCA cell lines for expression and cellular localization 
of NGAL and MMP9 by Western blotting, Immunofluorescence (IF) and flow 
cytometry (FC) studies, towards investigating their utility as theragnostic 
agents in vitro and in vivo. Evidence of extracellular secretion of biomarkers 
would be assessed by Enzyme-linked Immunosorbent Assay (ELISA) 
studies to highlight the value of targeting these markers in tumour stroma.  
c) To evaluate the utility of CD105 and VEGFR2 as endothelial targets by IHC 
on FFPE PH-CCA tissue and correlate MVD to clinicopathological 
parameters. 
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d) To examine the efficacy of a targeting strategy using MBs through in vitro 
studies. 
e) To set up a murine subcutaneous xenograft model of EH-CCA using suitable 
cell lines.  This would enable the assessment of a MB-based targeted 
delivery system using vascular ligands in a pre-clinical model of CCA. 
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2 Materials & Methods 
2.1 Tissue Blocks & Ethics 
 
A notice of Substantial Amendment to the concurrent local study on usage of biliary 
proteomics in the development of diagnostic markers of biliary malignancy was 
submitted to the Leeds East NRES Committee, to include the additional study of 
archival paraffin embedded tissue samples. Following approval (REC 
06/Q1206/136; 18th July 2011; Section 7.1), peri-hilar CCA tissue blocks from  54 
patients who underwent surgical resection of these tumours at this institution from 
January 2000 to September 2010 were acquired with the kind assistance of Dr Judy 
Wyatt, consultant histopathologist at St James’s University Hospital, Leeds. Blocks 
of matched normal liver tissue where possible were also obtained and subjected to 




Immunohistochemistry protocols for antibodies to NGAL and MMP9 were optimized 
for antibody concentration and retrieval method. Protocols for optimal staining of 
CD31, CD105 and VEGFR2 antibodies were already established in our laboratory. 
 




My decision to focus on the proteins NGAL and MMP9 was determined by the 
results obtained by prior work at our institution into biliary proteomics  in CCA 
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patients (Farid, 2014), which identified these two proteins as being secreted in 
relatively high amounts in bile. This group in the course of their work optimized the 
following antibodies for Western blot applications on bile: 
 
 Mouse monoclonal Anti-NGAL (Abcam, Cambridge; ab23477) 
 Mouse monoclonal Anti-MMP9 (Abcam, Cambridge; ab58803) 
 
As these antibodies are specified as being additionally suitable for 
Immunohistochemistry applications, they were selected upfront for these 
experiments. As elaborated in detail later, the final choice of antibodies changed 
based on the experiments conducted, as the original choices were not without their 
drawbacks. 
 




Five micron-thick tissue sections were cut from FFPE tissue blocks using a tissue 
microtome (Leica RM2235) and fixed onto glass slides (Superfrost Plus®, Thermo 
Scientific) overnight at 37°C.  Sections were dewaxed and hydrated using a series 
of xylene, ethanol and water steps. Antigen retrieval was performed if necessary 
(see specific details for each antibody in the following sections) before endogenous 
peroxidase quenching with 0.3% v/v hydrogen peroxide for 10 minutes. Primary 
antibodies were diluted in Antibody diluent reagent solution (Invitrogen, Camarilo, 
CA) before application to sections. Sections were washed in Tris-buffered saline 
with 10% Tween-20 (TBS-T) for 5 minutes (x2) followed by 5 minutes in TBS alone, 
after primary incubation.  Following incubation with a Horseradish peroxidase 
(HRP)-conjugated secondary antibody, washes were repeated as detailed above. 
Incubation with 3,3'-diaminobenzidine tetrahydrochloride (DAB)+ Substrate 
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Chromogen System (Dako, Carpinteria, CA) revealed the expression pattern of the 
antibody. Sections were counterstained with Haematoxylin, ’blued’ in Scott’s tap 
water then dehydrated through ethanol and xylene.  Sections were permanently 
mounted using DPX (Sigma, UK) under a glass coverslip. Serial tissue sections 
were used for endothelial cell staining protocols (CD31, CD105 & VEGFR2) in order 
to study similar regions across sections. No-primary (Secondary antibody only) 
slides were included in all runs to establish that staining was specific for the primary 
antibodies used and appropriate in-house positive controls were used. 
 
2.1.1.2.1 NGAL and MMP9 
 
 
These antibodies required optimization to identify ideal dilutions, as elaborated in 




The primary antibody used was an anti-human CD31 mouse monoclonal antibody 
(Dako, Glostrup, Denmark, Clone JC70A) at 1/40 dilution with overnight incubation 
at 4°C. The Dako EnVision™ System-HRP as detailed above for MMP9 was 





Antigen retrieval was performed by immersing sections in 100μl Proteinase-K 
enzyme (20μg/ml) in 50ml phosphate buffered saline [PBS]) for 25 minutes at 37°C 
in a water bath. A mouse monoclonal anti-human CD105 antibody (Dako, Glostrup, 
Denmark; Clone SN6H) was applied at 1/20 dilution for 1 hour whilst the Dako 
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A section of mouse subcutaneous tissue was used to stain hair follicles as a 
positive control.  Antigen retrieval was performed by heating sections in 0.05 M Tris-
EDTA pH 9.0 buffer at 800W in a microwave for 5 minutes. A Casein block was 
utilized before addition of a rabbit monoclonal anti-human/mouse VEGR Receptor-2 
antibody (Cell Signaling Technology, MA) at 1/100 dilution for one hour at room 
temperature. Secondary incubation was carried out using the Dako EnVision™ 
System-HRP for use with rabbit primary antibodies (Dako, Carpinteria, CA). 
 
2.1.1.3 Visual scoring of staining intensity 
 
 
For quantitation of MMP9 and NGAL IHC staining, the Histoscore method (Jonat et 
al., 1986) was adopted . Briefly, using an Olympus CHA microscope, CCA tumour 
tissue was identified in each section, at x40 magnification. Subsequently, at x400 
magnification (=1 High Power Field [HPF]), a maximum of 100 tumour epithelial 
cells were assessed for intensity of staining, from 0 (none) to 3 (highest) per cell. 
This step was repeated across 10 HPFs and the total numbers of cells for each 
intensity recorded. The Histoscore was calculated using the formula: H= P (i+1) 
 Where H= Histoscore for a given intensity 
 P= percentage of cells positive for a given intensity 
score 
 i= Intensity score 
The net sum of histoscores for all intensities per section yielded the final Histoscore, 
which was recorded. 
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Estimation of vascular staining was performed by calculation of MVD as previously 
described (Weidner, 1995). At x40 magnification, 3 areas of highest vascular 
density (“hot spot”) were identified on the CD31 tissue section, preferably at tumour 
margins. Subsequently, at x200 magnification, the number of discrete endothelial 
staining patterns per field (x3) was counted. These steps were repeated for 
adjacent CD105 and VEGFR2 sections in the same fields as were used for CD31 
MVD assessment. The final MVD score per antibody was the average of counts 
from all 3 fields per section. All scores for the initial third of cases were recorded by 
two independent observers (AN and EV) blinded to clinical parameters related to 
the assessed tissue sections. If the degree of disagreement between scorers was 
substantial, scores were re-done by combined assessment.  The latter two thirds of 
cases were scored solely by AN. 
 
2.2 Patient database 
 
 
Details of all 54 patients whose tissue blocks were sourced for IHC studies were 
retrieved from a prospectively maintained database held within the Department of 
Hepatobiliary and Transplant Surgery at St James’s University Hospital, Leeds.  
Anonymised clinical parameters including age at surgery, gender, details of surgical 
procedure were collected, in addition to follow up data such as times to 
recurrence/metastasis, demise or last follow up, as the case may be. Pathological 
parameters looked into included details of TNM staging (as per the 7th edition of the 
AJCC system for peri-hilar CCA), tumour size and grade, nodal positivity, 
microscopic vascular invasion and resection margin status. 
 
 83 
2.3 Cell lines 
 
Cholangiocarcinoma cell lines were sourced from various repositories and as gifts 
from allied institutions, as detailed in Table 7. 
 
Cell lines were grown in 10% (v/v) foetal calf serum (Invitrogen, UK) with RPMI 
medium (Life Technologies), with the exception of 2 cell lines: EGI-1, which required 
DMEM medium (Life Technologies) with 10% FCS, and H69, which required a 
specially formulated medium (7.2). All lines were maintained in an incubator at 37°C 
with 5% carbon dioxide in 75cm2 flasks with a canted neck and vent cap (Corning, 
Acton, MA). Cells were passaged before confluence using trypsin and were then 
seeded into fresh flasks at 1/5 to 1/10 dilutions. 
Once obtained, all cell lines were authenticated in-house using Short Tandem 
Repeat analysis with the kind assistance of Dr Claire Taylor, Genomics Facility, 




Approximately 5 x 105 cells in 2 ml of medium were seeded onto a glass coverslip in 
a 6 well plate and incubated for 2 days. At confluence, adherent cells were fixed 
with 4% v/v paraformaldehyde (PFA) to enable membrane-bound proteins to be 
studied. During optimization of primary antibodies for immunofluorescence and 
Western blotting, the anti-MMP9 and anti-NGAL mouse monoclonal antibodies from 
Abcam used for IHC were found not to be suitable for IF applications and hence 
alternatives were optimized. As the IHC run on all CCA sections with the Abcam 
anti-MMP9 antibody had been completed by this stage, equivalent staining by IHC 
was demonstrated between Abcam and my final choice of antibody for IF 













Cell line Derivation Source Reference 
EGI-1 EH-CCA DSMZ, Germany N/A 
TFK-1 EH-CCA DSMZ, Germany (Saijyo et al., 1995) 
HuCCT-1 IH-CCA JCRB, Japan (Miyagiwa et al., 1989) 
Huh-28 IH-CCA JCRB, Japan (Kusaka et al., 1988) 
OZ EH-CCA JCRB, Japan (Homma et al., 1987) 
SkChA-1 EH-CCA Gifted by Mr Rob Hutchins, 
Imperial College, London 
(Knuth et al., 1985) 
H69 Normal cholangiocytes (Grubman et al., 1994) 
SVR 
Murine pancreatic islet 
endothelium 
ATCC, USA (Arbiser et al., 1997) 
Table 7: Cell lines used in this study 
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Primary antibodies were applied as follows: 
 
NGAL 
 Goat polyclonal NGAL (R&D Systems, Minneapolis, MN; AF1757); 1-hour 
incubation at 1/50 dilution 
 
MMP-9 
 Rabbit polyclonal MMP9 (Chemicon, Temecula, CA; ab13458); 1 hour 
incubation at 1/100 dilution (the Abcam MMP9 antibody did not yield positive 
results for Immunofluorescence applications in my cohort of cell lines) 
 
CD105 
 Monoclonal Rat anti-mouse CD105 (Clone  MJ7/18 , BD Pharmingen; 
550546); 1 hour incubation at 1/50 dilution 
 
 
‘No-primary’ (secondary antibody only) slides were included to define any non-
specific staining. Following washing with TBS, a secondary fluorophore-conjugated 
antibody was added as follows for 30 minutes in the dark, as follows: 
 For NGAL primary antibody: 1/300 dilution (in TBS) Donkey anti-goat 
Alexafluor 488 (Invitrogen; Cat A11055), or 
 For MMP9 primary antibody: 1/300 dilution  (in TBS) Donkey anti-rabbit 
Alexafluor 594 (Invitrogen; Cat A21207), or 
 For CD105 primary antibody: 1/300 dilution (in TBS) Donkey anti-rat 
Alexafluor 594 (Invitrogen; Cat A-21209) 
 
Further TBS washes were performed in the dark. Coverslips were mounted onto 
glass slides (Superfrost Plus®, Thermo Scientific) using Prolong® Gold antifade 
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reagent with 4', 6-diamidino-2-phenylindole (DAPI) (Invitrogen, Eugene, OR; 
P36931). This mountant was allowed to dry in the dark overnight and the edges of 
the coverslips were sealed with nail polish. A Zeiss Axioimager.Z1 apotome 
fluorescent microscope (Carl Zeiss, Thornwood, NY) was used to image the cells. 
Exposure times on the microscope were obtained using the Zeiss AxioVision 
software and were standardized to the brightest cell line in each antibody run, so as 
to assess relative staining intensities between different cell lines. 
 
2.3.2 Western blotting 
2.3.2.1 Cell lysates and protein quantification 
 
 
Whole-cell lysates were made from confluent cultures of all seven cell-lines (Table 
7). Briefly, cells were washed with serum-free media before addition of ice-cold lysis 
buffer solution (consisting of a 1:1 mix of 2X radio-immunoprecipitation assay 
(RIPA) buffer (10mM Tris HCl pH 7.4, 300 mM NaCl and 2% NP40) and ‘cOmplete’ 
Protease Inhibitor Cocktail (Roche, Mannheim, Germany) 2X solution). Following 
incubation at 4°C for 10 minutes, cells were scraped off and the resultant solution 
centrifuged at 16000x g for 10 minutes. The supernatant was stored in aliquots at    
-80°C. 
 
Lysates enriched for cell membrane proteins were similarly collected using the 
ProteoExtract® Transmembrane protein extraction kit (Novagen®; 71772-3) as per 
manufacturer’s instructions. Cytoplasmic extracts were also obtained as a result of 
this process. All samples were stored at -20°C. 
 
Protein standardization was performed with the Bio-Rad DC™ protein assay 
reagents package (Bio-Rad; 500-0116) using the manufacturer’s instructions and 
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analysed at 630nm using a Dynex OpSys MR™ microplate photometric reader 
(Dynex, Chantilly, VA). A standard curve incorporating linear regression points of 
increasing dilutions of bovine serum albumin standards (2, 1, 0.5 and 0.1 mg/ml) 
was constructed and corresponding concentrations of test samples (lysates) were 
extrapolated from this. 
 
2.3.2.2 Protein extraction and gel electrophoresis 
 
A standard amount of protein (ranging from 10-30μg) was mixed with a 5:1 mixture 
of 2-mercaptoethanol (Sigma-Aldrich). NuPage® LDS 4X Sample buffer (Invitrogen, 
Carlsbad, CA) was added with de-ionized water to equalize volumes of all test 
samples and achieve a final 1X concentration of sample buffer. These were then 
denatured at 100°C for 5 minutes, and then stored on ice until gel loading. 
 
NuPage® 12% Bis-Tris 1.0mm x 10 well Gels (Novex, Carlsbad, CA) were used for 
gel electrophoresis. Gels were placed in a XCell SureLock™ Mini-cell 
electrophoresis system (Invitrogen, Carlsbad, CA). The system was filled with a 1X 
NuPage® MOPS SDS Running buffer (Invitrogen, Carlsbad, CA). Samples were 
then loaded into the wells, alongside 5μl of MagicMark™ XP Western Protein 
Standard (Invitrogen, Carlsbad, CA) and 15μl Color Plus Prestained Protein Marker 
(New England BioLabs, Ipswich, MA). The gel was run at at 180V for 60-120 
minutes (Bio-Rad Power Pac 300), allowing larger molecular weight proteins  more 
time to migrate down the gel. 
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2.3.2.3 Protein transfer 
 
A polyvinylidene fluoride (PVDF) membrane (Thermo Scientific, Rockford, IL; 
88518) was cut to the size of the gel and activated by immersed in methanol for 30 
seconds. The gel was placed on to the activated membrane, and flanked on either 
side with filter paper. This was sandwiched between several layers of sponge that 
had been soaked in the transfer buffer and loaded into a XCell II Blot Module 
(Invitrogen, Carlsbad, CA). The module was placed into the mini-electrophoresis 
system and 1X NuPage® Transfer buffer (Invitrogen, Carlsbad, CA; NP0006-1) 
containing 10% methanol was poured into module until the sandwich was 
submerged. De-ionized water was then poured into the outer chamber of the 
system. Protein transfer was performed at either 12V overnight or 30V over 90 
minutes. 
 
2.3.2.4 Protein blocking 
 
The PVDF membrane once removed from the assembly was immersed in Ponceau-
S to ensure equal protein transfer by visualization of proteins. This was washed off 
in deionized water, and the membrane was placed in a 5% (w/v) milk powder 
solution (Marvel in TBS) on a Denley Spiramix roller mixer machine for one hour. 
 
2.3.2.5 Antibody incubation 
 
 
Antibodies were diluted in a 1% (w/v) skimmed milk solution containing the 
membrane using the following dilutions: 
 
 NGAL (R&D Systems, Minneapolis, MN; AF1757): 0.1 μl/ml for 1 hour at 
room temperature 
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 MMP9 (Chemicon, Temecula, CA; ab13458; 1 mg/mL): 1/250 for 2 hours at 
room temperature (the Abcam MMP9 antibody did not yield positive results 
for Western blot applications in my cohort of cell lines) 
 
For assessment of equal protein loading, the following antibodies were used: 
 Mouse monoclonal β-actin (Clone AC-15, Sigma-Aldrich, St Louis, MO; 
A5441): 1/20000; or 
 Mouse monoclonal α-tubulin (Clone B-5-1-2, Sigma-Aldrich, St Louis, MO; 
T5168): 1/5000 
 
The membrane was then washed in 3 x 10 minute washes of TBS-T before the 
appropriate HRP conjugated secondary antibody was added as follows: 
 Polyclonal swine anti-rabbit Immunoglobulin-HRP (Dakocytomation, 
Glostrup, Denmark; P0217): 1/2000 
 Polyclonal rabbit anti-mouse Immunoglobulin-HRP (Dakocytomation, 
Glostrup, Denmark; P0260): 1/2000 
 Polyclonal rabbit anti-goat Immunoglobulin-HRP (Dakocytomation, Glostrup, 
Denmark; P0449): 1/2000 
 








2.3.2.6 Protein detection 
 
 
The SuperSignal® West Pico Trial kit (Thermo Scientific, Rockford, IL; 34079) was 
reconstituted as per manufacturer’s instructions and the resultant solution poured 
on to the membrane. Images were acquired after 5 minutes using a Bio-Rad Gel 
Doc Imaging system and Image Lab™ software (Version 4.0.1).  If protein bands 
were not detected using the Pico kit, the membrane was washed in TBS-T before 
application of the SuperSignal® West Femto Trial kit (Thermo Scientific, Rockford, 
IL; 34094). Densitometric assessment of Western blot images was done using 
ImageJ software v1.49 for Windows (http://rsb.info.nih.gov/ij/download.html). 
 
Once images were obtained, membranes were washed again and then immersed in 
TBS for storage in an airtight container at 4°C (short-term) or -20°C (long-term). 
 
2.3.3 Flow cytometry 
 
2.3.3.1 Flow cytometry protocol 
 
To clarify the cell surface expression of MMP9 and NGAL on CCA cell lines, FC was 
utilized. As no fluorophore-conjugated Anti-MMP9 and anti-NGAL antibodies 
suitable for FC applications were readily at my disposal, I sought to titrate 
fluorophore conjugated secondary antibodies against my  primary antibodies from 
Abcam suited for FC. Briefly, confluent 75cmm cultures of CCA cells were treated 
with 5mM EDTA for 10 minutes at room temperature, before trypsinization and 
centrifugation at 400g for 5 minutes. The cell pellet was resuspended in 5% Fetal 
calf serum/PBS mixture and cells counted in a Neubauer chamber. Cells were re-
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suspended to a count of 107 cells/ml. A volume of 50μL of cells was added to a Flow 
cytometer tube and the following antibodies were added: 
 
Primary 
 Mouse monoclonal anti-NGAL (Abcam, Cambridge; ab23477), or 
 Rabbit monoclonal anti-MMP9 (Abcam, Cambridge; ab76003) 
 
Secondary (at 1:50 dilution) 
 Pacific blue™ Goat anti-mouse (F(ab')2 fragment) IgG (Invitrogen, Carlsbad, 
CA; P31581), or 
 Alexafluor 488 Goat Anti-Rabbit IgG (Invitrogen,Carlsbad, CA; A11008) 
 
The primary antibodies were added as per Table 13 and tubes incubated on ice for 
30 minutes in the dark. 2mls of 5%FCS in PBS was added per tube and centrifuged 
for 5 mins at 400g at 4°C. The supernatant was flicked off before adding secondary 
antibodies as detailed in the table. Incubation in the dark for 30 minutes on ice was 
again undertaken, followed by adding 5%FCS/PBS and centrifugation as before. 
Finally 50μL of diluted 7-Amino-actinomycin D (7AAD) (BD Biosciences, San Jose, 
CA; 51-68981E) was added as per the table before incubation on ice in the dark for 
10 minutes, to highlight non-viable cell populations. Samples were then taken to the 
Flow cytometer for analysis. 
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2.3.4 NGAL Enzyme linked immunosorbent assay (ELISA) using 
CCA cell line supernatants 
 
The Quantikine NGAL ELISA kit (R&D Systems, MN, USA) was employed as per 
the manufacturer’s directions for the purpose of quantifying NGAL secretion into 
CCA cell culture supernatants. Briefly, supernatants were separated by 
centrifugation of confluent cultures to separate out particulate matter and the former 
immediately frozen in aliquots at -20°C until the time of assay. After preparation of 
the NGAL Standard solutions, 1/20 dilutions of samples were mixed with an Assay 
diluent solution in each well of a 96-well plate coated with NGAL antibody and 
incubated for 2 hours at 2-8°C. The wells were then emptied and washed (x4) with 
Wash buffer, following which NGAL conjugate was added to each well. Further cold 
incubation for 2 hours ensued. Another set of wash cycles was then performed, 
after which Substrate solution was placed in each well for 30 minutes away from 
light. Finally a Stop solution was added, followed by reading of the plate in a 
microplate reader at 570nm. Optical density results from the reader were 
extrapolated to actual concentrations using the standard curve constructed with the 
NGAL Standard solutions. 
 
 
2.3.5 In vitro flow assays using CD105 labelled Micromarker and 
Microfluidics Microbubbles on the SVR cell line 
 
 
In vitro assays to ascertain the degree of binding of CD105 target antibody-labelled 
microbubbles to murine Sven-1 Ras (SVR) cell lines were conducted as follows: 
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2.3.5.1 Targeted (CD105) Microbubble preparation 
 
Two types of MBs were utilised separately in the flow assay experiments:. 
Microfluidics MBs produced in-house and those commercially obtained viz. 
Micromarker™ (Vevo Visualsonics). 
 
2.3.5.1.1 Microfluidics Microbubbles 
 
These MBs were synthesized in-house using methods described in detail previously 
(Peyman et al., 2012), enabling the production of a largely monodispersible 
(homogenous) population of MBs of average diameter 2-5µm, in concentrations 
>108 ml-1 in line with what clinical applications mandate to prevent the risk of end 
organ embolism and ischaemia. Briefly, 2mg of a 6:1 mixture of dried lipids (DPPC; 
Dipalmitoylphosphatidylcholine) and biotinylated Pegylated 1,2-Distearoyl-sn-
glycero-3-phosphoethanolamine (DSPE-PEG(2000) Biotin) (Avanti Polar Lipids, 
Alabaster, Al, USA) was dissolved in 1 cc of bubble buffer (consisting of a solution 
of 4% Sodium chloride and 1% glycerol) before being subjected to sonication in a 
bubble bath, typically over 45 minutes until a homogenous cloudy solution was 
obtained. NeutrAvidin® Biotin-binding Protein (Molecular Probes, Life Technologies, 
UK) was then added to this mixture (at 16.67µM) to enable cross linking of 
biotinylated MBs with biotinylated target antibody in the final step of synthesis. After 
vortexing, the solution was stored at 4°C for 20 minutes before use. 
 
The next step in manufacture involved set up of the microfluidics chip assembly as 
schematically illustrated in Figure 14. These tailor made polycarbonate-epoxy chip 
devices (Epigem, Redcar, UK) provide an interface for gas and lipid interaction to 
form MBs. They incorporate separate microchannels for gas and liquid flow in either 




Figure 14: Epigem microfluidics chips used for MB manufacture  
 
a- single module; b- multiplex module; c: Assembly incorporating microchip and gas/liquid 
lipid inlet channels with outlet channel to reservoir collecting new MBs. Taken from 
Peyman et al. Expanding 3D geometry for enhanced on-chip microbubble production and 
single step formation of liposome modified microbubbles. Lab Chip, 2012; 12: 4544-4552 




production. An abrupt increase in diameter of the combined output channel at the 
meeting point of the narrower gas and liquid inflow channels causes an acute 
pressure drop at this point leading to MB generation. A manifold apparatus clamps 
down the chip on to a stage sealing the whole system and rendering it gas-tight. 
 
Perfluoropropane gas (C3F8) was delivered at 13.5psi through the gas inlet channel 
of the chip, whilst the cooled lipid solution was administered through the liquid inlet 
channel via a 0.4µm filter using a motorised syringe driver (World Precision 
Instruments, FL, USA) at 20 µL min-1. The adequacy of MB production was 
qualitatively assessed in real time by means of an inverted light microscope 
(Eclipse, Nikon, Japan) whose objective lens (x10) was placed under the bubble 
generation area. 
 
Once collected, MB concentration was calculated by means of a bespoke counting 
chamber and the ImageJ software (http://imagej.nih.gov/ij/index.html). 
 
The rat anti-mouse biotinylated CD105 antibody (eBiosciences, CA, USA; Cat 13-
1051) and its IgG2a isotype control (Stock solution 0.5 mg/ml) were added to 
separate MB solutions in concentrations of 0.1 µg/107 MBs, 0.05 and 0.01 µg/107 
MBs respectively as part of serial optimization flow assays for the antibody. 
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2.3.5.1.2 Micromarker microbubbles 
 
 
Micromarker™ (Vevo Visualsonics Target-ready contrast agent) MBs were 
reconstituted as per the manufacturer’s instructions. Briefly, target-ready contrast 
agent was rehydrated with 700ul of PBS by direct injection into the containing vial. 
The administering 21G needle was momentarily left in place through the cap to 
equilibrate pressures across it, after which the needle was withdrawn and the vial 
gently agitated for 10 seconds before being left at room temperature for 5 minutes. 
The resultant final MB concentration in the vial was 2 x109 MBs ml-1.  
Biotinylated CD105 antibody (eBiosciences, CA, USA; Cat 13-1051) was then 
added to the solution at 10µg per 109MB, and following subsequent agitation for a 
minute, left for 15 minutes at room temperature prior to use. Again, 107 MBs were 
utilised per flow assay experiment. 
 
2.3.5.2 Ibidi slide plating and Flow assay experiments 
 
To simulate the shear stress conditions of capillary blood flow in an in vitro model 
and thus determine the targeting capabilities of ligand coated microbubbles in such 
an environment, flow assays were set up as described by McLauglan and co-
workers (McLaughlan et al., 2013). Briefly, 30µL of 5 x 105 SVR cells/ml were each 
plated into 6 channels of a µ–Slide VI 0.4 (Ibidi, Martinsried, Germany) and the latter 
incubated at 37°C in 5% carbon dioxide for 48 hours until cells reached 
approximately 80-90% confluence. To allow the cells to grow on the upper surface 
of the channels, slides were initially stored in an inverted position. The flow assay 
assembly consisted of a motorised syringe driver pump (World Precision 
Instruments, FL, USA) with adjustable flow rate, net volume and syringe diameter 
functions. Following 3 initial PBS flush cycles to clear away culture media and loose 
cells, the driver delivered 107 MBs (suspended in PBS) at a rate of 0.2mls min-1 for 
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5 mins via a flexible connector tubing connected into the reservoir at one end of the 
Ibidi chip channel. Fluid once traversed the channel collected into a reservoir at the 
opposite end and continued on into a waste pot via a second segment of connector 
tubing. A further cycle of PBS wash was delivered before analysis of the flow 
channels under inverted light microscopy (x40 magnification) for MB binding. Using 
a digital camera in-line with the optics of the microscope, 5 images were taken of 
different fields within each flow channel. MBs were identified in these images as 
double layered refractile rounded objects. The number of MBs bound to (i.e. in 
contact with) SVR cells was counted in each image, along with the total number of 
SVR cells in that field. This process was repeated for all 5 images and the degree of 
binding expressed as a ratio of bound MBs to total cells. 
 
 




CD1 nude (nu/nu) and Balb/c congenitally athymic female mice (originally sourced 
from Charles River Laboratories, Margate, Kent and subsequently maintained in-
house) were utilized for xenograft work. All mice were specific pathogen free (SPF) 
and maintained in a dedicated facility ensuring high standard health conditions. 
They were housed in individually vented cages (IVC) with food and water provided 
ad libitum. All interventions were approved by the UK Home Office and carried out 
as per the Animals (Scientific Procedures) Act 1986 regulations. 
  
To develop and in vivo model in which to test targeted therapies, all 7 CCA cell lines 
were assessed for their potential to grow  as heterotopic (subcutaneous) xenografts 
in these immunodeficient  mice. Briefly, CCA cell lines were grown to confluence in 
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several 150cm2 flasks (Corning, Acton, MA) before trypsinization and centrifugation 
down to a pellet of cells. Cell counts were carried out using a Neubauer chamber 
and the total number of cells in solution was calculated to the volume, adjusted to 
achieve the intended cell number (5-10 million cells) in 100μl injection volume in 
serum-free medium. Injections were made into the subcutaneous region of either 
flank of the nude mouse after application of topical anaesthesia. Tumour growth 
was measured weekly using calipers. Xenograft volume was calculated using the 
modified ellipsoid formula: 
 
 v = 0.5 (l x b2) mm3 
 
where v= volume, l= length (mm) & b= breadth (mm) of the xenograft (Tomayko and 
Reynolds, 1989). Growth curves for each cell line were generated as shown in 
Figure 15. Appreciable tumour growth was seen only in 3 cell lines, and on 
occasion, spontaneous tumour regression as also observed. 
 
After 6 weeks from inoculation, or following experiments, mice were sacrificed and 
xenografts harvested as appropriate. Tumours were fixed in 4% (v/v) PFA and 
embedded in paraffin, prior to obtaining tissue sections for Haematoxylin/Eosin 
(H&E) staining or immunohistochemistry. 
  
 99 
2.4.2 In vivo binding assays with CD105 labelled Microbubbles on 
CCA xenografts using High Frequency Ultrasound 
assessment 
 
Experiments were conducted approximately 4-6 weeks following subcutaneous 
injection as described previously. Firstly, Target-Ready MBs/Targeted Vevo 
MicroMarker™ Contrast Agent (VisualSonics, Toronto, ON, Canada; Bracco 
Research, Geneva, Switzerland) for injection were prepared as per the 
manufacturer’s instructions. Briefly, to one vial of Target-Ready MBs (containing 
2x109 MBs), 20µg in PBS of anti-mouse CD105 antibody (R&D Systems/ AF1320) 
or IgG isotype control was added and the net volume made up to 1000 µL PBS.  
 
Under inhaled Isoflurane anaesthesia administered by face mask at 2L/min, mice 
were fastened to an electroconductive board that allowed real time monitoring of 
heart rate and temperature. This assembly was placed under a warming light. A 40-
MHz linear transducer high-frequency US probe (RMV-704; VisualSonics) was 
placed over the xenograft and real time imaging performed using the Vevo 770 
system (Fujifilm VisualSonics).  
 
Two-dimensional US mode was used to identify the centre (largest diameter) of the 
xenograft and then the probe was fixed into position on the assembly. The tail vein 
of the mouse was identified for intravenous injection. 
 
Using a tail vein catheter, initially 50 µL (equivalent to 108 MBs) isotype control MBs 
was injected at a rate of 0.6ml/min using a motorised syringe driver. Four minutes 
were given to allow injected MBs to bind to xenograft vasculature and readings 
were saved. Subsequently, a destructive US pulse (10 MHz) was administered 
 100 
through the fixed probe and readings obtained again. This process was repeated for 
CD105 MBs after a lapse of 10-20 minutes, to allow isotype control MBs to be 
eliminated from the circulation. 
 
In the post-processing phase, the VisualSonics software was utilised to generate a 
3-dimensional image and volume of the tumour. This was performed by outlining the 
xenograft border using the software every 10-20 frames. Next, the final 100 frames 
in sequence from the experiment (for each antibody run) was taken as a baseline to 
calculate signal amount from bound and flowing MBs (pre-destruction pulse) and 
that from flowing MBs alone (post-destruction pulse). Subtraction of the latter from 
the former gave the subtracted molecular signal (i.e. signal due to bound MBs 
alone), indicative of the amount of CD105 receptors in the scanned vasculature. If 
the subtracted molecular signal was higher with CD105 MBs in comparison to that 
of isotype control MBs, specific binding was deemed as having occurred. 
 
2.4.3 CD105 Immunohistochemistry of Xenograft sections 
 
 
Following in vivo experiments with CD105 tagged microbubbles, CCA xenografts 
and mouse tissue (liver, spleen and kidneys) were harvested and paraffin 
embedded prior to microtome sectioning as described previously. Five micron 
sections were dewaxed and hydrated as detailed previously. No antigen retrieval 
was required. Endogenous peroxidase activity was quenched and Avidin-Biotin 
block done using a blocking kit (Vector, Burlingame, CA). A Casein block (Vector, 
Burlingame, CA, diluted in Antibody diluent reagent solution) was incubated with the 
sections for 20 minutes to reduce background staining further. A goat polyclonal 
anti-mouse CD105 antibody (AF 1320, R&D Systems, Minneapolis, MN) was used 
at 1/500 dilution for 1 hour at room temperature. A polyclonal rabbit anti-goat 
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biotinylated immunoglobulin (Dako, Carpinteria, CA) was utilized at 1/200 dilution 
for 30 minutes, for secondary incubation. The Vectastain® Elite® ABC kit (Vector, 
Burlingame, CA) was then added to sections before addition of DAB. Sections were 
finally dehydrated through ethanol and xylene before coverslips were mounted 
using DePex mounting fluid (Sigma, UK) and slides dried overnight in a fume 
cupboard. 
 
Additionally, Haematoxylin and Eosin staining of harvested xenograft sections was 
performed separately. Five-micron sections were deparaffinised in xylene followed 
by hydration in ethanol. Slides were immersed in Haematoxylin (Sigma, UK) for 1 
minute followed by one minute rinse in tap water. Slides were then incubated in 1% 
(v/v) Eosin (Sigma, UK) for one minute and rinsed under tap water for one minute. 
These were then dehydrated and mounted as described above. 
 
2.5 Statistical analysis 
 
The statistical software package SPSS version 22 (IBM, Armonk, NY, USA) was 
used for data analysis, with a p value <0.05 used to denote statistical significance. 
Categorical variables were analysed using the Fisher’s exact test whereas the 
Mann-Whitney U test was used for comparisons between continuous data. 
Correlations between continuous variables were assessed with the Spearman test, 
and the Wilcoxon signed rank test was utilised for matched tissue comparisons. 
Using an online tool (http://molpath.charite.de/cutoff) (Budczies et al., 2012), 
analysis of the AUC-ROC of NGAL and MMP9 Histoscores was performed to 
determine optimal cut-off points predictive of nodal metastasis and mortality. This 
tool was also utilised for dichotomising continuous variables at the best cut-off for 
survival analysis.  Survival curves were generated using the Kaplan-Meier method 
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and differences between proposed predictive factors assessed using the log rank 
test. Censoring of data towards calculation of survival statistics was done for all 
cases of peri-operative death, patients who died later due to non-CCA related 
causes/lost to follow up and in those alive at the end of 5 years. Factors found to be 
significantly associated with mortality on univariate analysis were entered into Cox 
regression models to ascertain independent determinants of survival. Graphs were 
generated with the use of GraphPad Prism v7 software for Macintosh (GraphPad 












The purpose of the experiments in this Chapter was firstly to ascertain the validity of 
NGAL and MMP9 as theragnostic biomarkers in CCA, in light of prior biliary 
proteomics work in our institution on PH-CCA patients that had shown these 2 
biomarkers to be overexpressed in comparison to control bile. This was evaluated 
by means of WB, IF, FC and ELISA techniques on various CCA cell lines.  I also 
sought to clarify whether any prognostic effect was evident with the tissue 
expression of either marker in the cohort of 54 patients with resected PH-CCA. IHC 
was conducted on all tissue samples and expression quantified by Histoscore 






3.2.1 Antibodies and their optimization 
 
Anti-MMP9 and anti-NGAL antibodies were tested on CCA sections (as 
summarized in  
Table 8 until optimal staining (i.e. balancing adequate tumour staining against 
minimum background staining) was achieved. Notable points regarding this process 











Table 8: Optimization strategies for MMP9 and NGAL antibodies used for IHC in the 
study  
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The anti-MMP9 antibody ab58803 (Abcam, Cambridge, UK) was optimized for IHC, 
and used with the EnVision™ detection system. Human ovarian tissue sections 
(from our gift tissue bank) were used as a positive control, and optimal tumour 
staining was obtained with a 1/100 dilution of antibody (Figure 15). Background 
staining in normal liver was seen at all dilutions, which can be attributed to a 
combination of factors viz. true expression of this marker in hepatocytes, along with  
elements of non-specific binding that is often seen in normal liver tissue despite the 
use of EnVision™ kits. Of note, this antibody was found not to work for Western 
blotting applications in spite of its datasheet advice to the contrary. In light of this, 
another MMP9 antibody (Chemicon, ab13458) present in-house was then tested 
and found to be reliable for Western blotting purposes.  To ensure the Chemicon 
antibody was detecting the same protein in tissues as the Abcam antibody, IHC 
staining patterns and intensities between the two antibodies  was evaluated (Figure 





My experience with the anti-NGAL antibody ab23477 (Abcam, Cambdrige, UK) on 
PH-CCA proved non-optimal as the staining observed, if any, was very weak in 
many of the tested sections. As a result, following a literature search for anti-NGAL 
antibodies used for IHC of CCA tissue, the R&D antibody AF1757 was chosen for 
use. Comparison of staining between these 2 antibodies is shown in Figure 17, and 






Figure 15: Optimization of MMP9 staining in normal liver and CCA tumour tissue 
 Top panels showing sections of normal liver (x4 magnification) and bottom panels CCA 
sections (x10 magnification). Comparison of staining using ab58803 (Abcam) at 1/50 (left 
half images) and 1/100 (right half images) antibody dilutions demonstrates less intense 









Figure 16: Comparative staining of Abcam and Chemicon anti-MMP9 antibodies. 
Staining from Abcam shown on the left half whereas that of Chemicon shown on the right half. 
Equivalence of staining by both antibodies at 1/100 dilution demonstrated in two different CCA 








Figure 17: Comparison of NGAL staining using 2 different antibodies.  
Top row (panels a, b, c) showing paucity of staining with Abcam anti-NGAL antibody at 1/25 dilution. Bottom row (panels d, e, f) demonstrating significantly 









Following blocking of endogenous peroxidase, Avidin-Biotin block was carried out 
using a blocking kit (Vector, Burlingame, CA). To reduce background staining 
further, casein block (Vector, Burlingame, CA, diluted in Antibody diluent reagent 
solution) was incubated with the sections for 20 minutes. A goat polyclonal anti-
human NGAL antibody (R&D Systems, Minneapolis, MN) was used at 1/100 dilution 
for 1 hour at room temperature. A polyclonal rabbit anti-goat biotinylated 
immunoglobulin (Dako, Carpinteria, CA) was utilized at 1/200 dilution for 30 
minutes, for secondary incubation. The Vectastain® Elite® ABC kit (Vector, 





A mouse monoclonal anti-human MMP9 (Abcam, Cambridge; 56-2A4, 1 mg/ml) at 
1/100 dilution for 1 hour at room temperature was used. The Dako EnVision™ 
System-HRP for use with Mouse primary antibodies (Dako, Carpinteria, CA) was 
utilized for secondary incubation for 30 minutes.   
   
 
3.2.3 NGAL and MMP9 are expressed in both CCA tissue samples 
and control normal liver tissue by Immunohistochemistry 
 
IHC for NGAL and MMP9 was performed on PH-CCA sections from 54 patient 
samples along with available matched normal liver tissue. In terms of localization, 
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expression of both markers was seen in tumour cell cytoplasm and membrane, 
along with variable degrees of stromal staining (Figure 18 and Figure 19). Staining 
of matched normal liver tissue revealed varying degrees of expression in 
hepatocytes and cholangiocytes. All tumour and matched liver sections expressed 
both markers to some extent.  
 
Both NGAL and MMP9 showed evidence of expression in tumour stroma in varying, 
albeit lesser intensities in comparison to corresponding tumour parenchymal cells..  
 
Quantitative assessment of expression of NGAL and MMP9 was performed by 2 
blinded scorers independent of each other (as detailed in the Methods section) for 
the first 20 cases. The correlation between their scores is shown in Figure 20. As 
demonstrated in this data, there was good agreement between both scorers in their 























































Figure 18: NGAL expression in PH-CCA tissue and matched control liver. 
 IHC showing strong expression in PH-CCA glandular tissue with mild stromal positivity (top 
panel). Also seen in the lower panel is diffuse staining of matched normal liver parenchyma, 
along with positivity of normal cholangiocytes in biliary radicles (arrow) within a portal triad. 
These findings were typical and representative of the whole cohort. 
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  Figure 19: MMP9 expression in PH-CCA tissue and matched liver control. 
 IHC demonstrating strong expression in PH-CCA glandular tissue and mild stromal staining 
(top panel). Once again, as seen in the lower panel, a substantial degree of parenchymal 
expression in seen in matched normal liver tissue, and within normal cholangiocytes (arrow). 
These findings were representative of the whole cohort. 
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Figure 20: Inter-observer correlations for NGAL and MMP9 Histoscores.  
Plotted data and line of best fit shown for both graphs. Top panel (n=19) showing data for 
NGAL (Spearman r=0.58, p=0.008) and bottom panel (n=20) showing data for MMP9 
(Spearman r=0.64, p=0.002). AN and EV denote the initials of the scorers. 
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3.2.4 Tumoural expression of NGAL is significantly higher than 
that of matched normal liver parenchyma 
 
The median (inter-quartile range) tumoural NGAL Histoscore was 327 (282-366), 
whereas the related figure for control NGAL expression was 200 (160-220). Figure 
21 demonstrates the Histoscores for PH-CCA tissue matched with control liver 
tissue. As can be seen in this illustration, Histoscore values in PH-CCA for NGAL 
were significantly higher in comparison to matched liver parenchyma (p<0.001), and 
that for MMP9 just achieving statistical significance (p=0.049). 
 
The paired NGAL and MMP9 Histoscores for all 54 patients are plotted as shown in 
Figure 22. This shows there was no statistically significant correlation between 











Figure 21: Plotted data of NGAL and MMP9 Histoscores in tumour versus matched 
control liver tissue.  
A significantly higher Histoscore was seen in tumour tissue compared to control liver with NGAL 
(p<0.001) (top panel; n=44) but for MMP9 was borderline significant (p=0.049) (bottom panel; 


























Figure 22: Scatter plot of NGAL versus MMP9 Histoscores in PH-CCA tissue, with the line 
of best fit shown.  
The correlation of Histoscores between these 2 markers was low (Spearman r=0.32) and this 
finding was statistically significant (p=0.017); n=54 
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3.2.5 Correlation of clinicopathological variables with NGAL and 
MMP expression. 
 
Clinicopathological variables for all 54 patients forming the study group were 
collated and analysed. The baseline patient parameters are summarised in Table 9, 
and were derived from analysis of the patient database as detailed in the Methods 
section. The median patient age was 57 years and the majority of the cohort was 
comprised of males (57%). The surgical procedure most commonly performed to 
resect the tumour was a right extended hepatectomy (35%). Notably, T1 disease 
was seen only in a minority of patients (4%) and most had evidence of lymph nodal 
involvement at surgery (54%).  
 
The associations if any between NGAL and MMP9 Histoscores and patient 
variables were next interrogated as demonstrated in Table 10. Interestingly, lymph 
nodal metastasis was found to be significantly associated with NGAL expression 
(p=0.021). The only other clinicopathological factor found to have a statistically 
significant association with NGAL and MMP9 expression was local recurrence. 
Experimental models of cholestasis have shown an association with hepatic NGAL 
expression (Borkham-Kamphorst et al., 2011) and therefore, a potential correlation 
between control liver NGAL expression and degree of pre-operative biliary 
obstruction was investigated as shown in Figure 23. However, no such association 






 Variable n (total = 54) % 
Median age (range) in years 57.6 (33-81)  
Gender     
Male 31 57.4 
Female 23 42.6 
Surgical procedure   
Left trisectionectomy (Segments 
2,3,4,5,8,±1) & bile duct excision 
18 33 
Left hemihepatectomy (Segments 2,3,4,±1) 
& bile duct excision 
7 13 
Right trisectionectomy (Segments 
4,5,6,7,8,±1) & bile duct excision 
19 35 
Right hemihepatectomy (Segments 
5,6,7,8,±1) & bile duct excision 
7 13 
Orthotopic Liver Transplant  2 4 
Bile duct excision alone 1 2 
Median Tumour size (range) in mm 30 (10-75)  
Tumour differentiation (grade)   
Well (G1) 27 50 
Moderate (G2) 19 35.2 
Poor (G3) 8 14.8 
Microscopic vascular invasion 33 61.1 
Perineural infiltration 48 88.9 
Tumour stage    
T1 2 3.7 
T2 29 53.7 
T3 19 35.2 
T4 4 7.4 
Nodal stage    
N0 25 46.3 
N1 21 38.9 
N2 8 14.8 
AJCC Stage (7th edition)   
I 0 0 
II 15 27.8 
IIIA 8 14.8 
IIIB 21 38.9 
IVA 2 3.7 
IVB 8 14.8 
Resection margin   
R0 (clear) 21 38.9 
R1 (involved) 33 61.1 
Local recurrence 5 9.3 
Table 9: Baseline PH-CCA patient characteristics 
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Variable n % 













>58 27 50 340 (288- 365) 280 (240-320) 
Gender       




Female 23 43 340 (295-370) 293 (250-340) 
Tumour size (mm) 




>30 28 54 340 (276-369) 282 (253-328) 
Histological grade       




Grade 2/3 27 50 331 (282-358) 284 (255-306) 
Microscopic 
vascular invasion 
      




No 18 35 336 (289-366) 280 (224-311) 
Nodal 
metastases 
      




No 25 46 310 (278-340) 280 (240-316) 




      




T3/T4 23 43 340 (250-380) 284 (245-330) 
Resection 
margins 
      




R1 (negative) 33 61 321 (281-362) 289 (247-325) 
Local recurrence       




No 49 91 340 (292-370) 289 (258-330) 
Metastasis       
Yes 26 48 340 (292-378) 0.21 292 (256-323) 0.32 
No 28 52 321 (272-359)  280 (230-325)  
       
Table 10: Comparison of NGAL and MMP9 Histoscores against clinicopathological 
patient variables.  
p-values of statistical significance in bold and italics (Mann-Whitney U tests). Local 
recurrence defined as recurrent disease within the surgical bed.  
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Figure 23: Scatter plot of control liver NGAL Histoscores against pre-operative serum 
bilirubin (µmol/L), with the line of best fit shown.  
Poor agreement between these variables was observed (Spearman r=0.22) though this 
finding is more likely due to chance than a true effect (p=0.31); n=23 
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3.2.6 No prognostic impact of NGAL or MMP9 expression is 
evident on patient survival in this cohort 
 
 
For the purposes of survival analysis, it was necessary to dichotomize the 
Histoscores of both NGAL and MMP9, thus rendering them categorical variables 
and enabling their analysis through log-rank statistical tests. Cognizant of the fact 
lymph nodal metastases are a prognostic determinant in PH-CCA and with the 
knowledge that NGAL Histoscores were predictive of nodal status in the cohort,  
I first identified a cut-off Histoscore of NGAL that best predicted this, and used this 
value to categorize this variable for survival analysis. As detailed in the Methods 
section, an online tool (Budczies et al., 2012) was utilised for this purpose. In the 
case of MMP9 Histoscores, the same tool was able to generate a cut-off that 
provided maximal separation of survival curves, whether statistically significant or 
not.  
 
Figure 24 displays a receiver operating characteristic (ROC) curve for NGAL which 
shows an optimal cut-off Histoscore of 345, giving a sensitivity of 59% and 
specificity of 80% for predicting lymph nodal metastasis. Using this cut-off value 
however did not yield any significant associations on survival analysis as shown in 
Figure 25 and Figure 26. Log-rank tests for MMP9 also did not reveal any cut-offs 








Figure 24: Receiver operating characteristic (ROC) analysis and Waterfall plot of 
NGAL Histoscore in predicting lymph nodal metastasis 
Top panel showing the ROC curve with an optimal cut-off of 345 (marked by the red cross). 
The lower panel displays a Waterfall plot of the accuracy of this cut-off for nodal metastasis 
in all 54 patients. Here, individual Histoscores are shown as correctly or incorrectly 



























Figure 25: Kaplan Meier curves for overall survival with NGAL Histoscore cut-off 345 
No significant difference in overall survival in seen in this instance (p=0.42) 
Figure 26: Kaplan Meier curves for disease-free survival with NGAL Histoscore 
cut-off 345. 
 No significant difference in disease-free survival is seen (p=0.37) 
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3.2.7 Characterising cellular expression of NGAL and MMP9 in 
CCA cell lines  
 
As NGAL was found to have a significant association with the occurrence of nodal 
metastases, this biomarker was the primary focus of my investigative efforts in this 
stage for its applicability to a targeting approach. A panel of EH-CCA and IH-CCA 
cell lines (Table 7) were selected based their frequent use in CCA research (Zach, 
2015)  to ascertain any differences in biomarker expression between them. There is 
a relative dearth of established PH-CCA cell lines, and amongst my selection, only 
OZ was stipulated as being derived from PH-CCA (Homma et al., 1987). 
Accordingly, for the purposes of my experiments, all tested EH-CCA cell lines were 
taken to be representative of both extra-hepatic and peri-hilar variants. In order to 
assess control expression, the normal cholangiocyte cell line H69 was included in 
my experiments. 
 
All experiments in this section were conducted primarily with a view towards 
establishing whether there was any membrane or stromal expression of NGAL, as 
this is a pre-requisite for a successful targeting strategy (van Oosten et al., 2011). 
 
3.2.7.1 Immunofluorescence of CCA and normal cholangiocyte cell 
lines 
 
CCA cell lines were assessed for localisation of NGAL and MMP9 by 
immunofluorescence (IF) staining. To minimize cellular permeabilization during 
fixation, the latter was performed with 4% paraformaldehyde as discussed in the 
Methods section.  
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For NGAL, the EGI-1 cell line gave the brightest staining intensity by preliminary 
visual assessment and hence was used for exposure standardization for image 
capture with all other cell lines (Figure 27). Using this as the reference image, 
expression in all remaining cell lines was scant (Figures 28-33). Only the IH-CCA 
cell line, HuCCT-1 and the normal cholangiocyte cell line, H69 showed a marginal 
degree of NGAL expression. 
 
 
With respect to MMP9, the cell line TFK-1 gave the brightest fluorescent signal on 
direct visualization under the fluorescent microscope and hence all captured images 
were standardized to its exposure settings (Figures 34-40). However, subsequent 
analysis of images showed Huh-28 as the highest expressor of MMP9.  This 
disparity may be due to difficulties in assessing differences in fluorescent intensities 
over background fluorescence accurately by eye. Comparison of staining intensities 
for both markers is shown below in Table 11. 
 
For both antibody runs, 4% PFA appeared to permeabilize the cell membrane 
(despite being free of methanol in its composition) and staining therefore was 
visualized mostly in the cytoplasmic component of all cells. The cell line OZ 
however did show specific membrane staining using this modality. 
 
In conclusion, the results of my IF experiments showed variable levels of NGAL and 
MMP9 expression within CCA cell lines and H69. Positivity was mostly noted in the 
cytoplasmic compartment, although membrane localization was noted in some 





Figure 28: IF for NGAL on HuCCT-1 
Relatively milder amounts of expression of NGAL is seen within cytoplasm in this instance 
See Figure 27 legend for layout of panels (x63 magnification)  
Figure 27: IF for NGAL on EGI-1  
Top left panel- DAPI nuclear staining, top right panel- NGAL visualized with FITC filter, 
bottom right panel- Merged image. A diffuse pattern of staining is seen intracellularly (arrow).  
Bottom left insert of 3 smaller squares show same image layout with omitted primary antibody 

























Figure 29: IF for NGAL on Huh-28 
No substantial expression is seen in comparison to the background staining seen with the 
no-primary run. See Figure 27 legend for layout of panels (x63 magnification) 
 
Figure 30: IF for NGAL on OZ 
 In this instance, membranous expression of NGAL is evident (arrow), although overall 






























Figure 31: IF for NGAL on TFK-1 
Marginal levels of NGAL expression is observed. See Figure 27 legend for layout of panels 
(x63 magnification) 
Figure 32: IF for NGAL on SkChA-1 
No-primary run with an equivalent amount of background staining, indicating near absent 






Figure 33: IF for NGAL on H69 
The normal cholangiocyte cell line showed appreciable levels of NGAL expression within 
cytoplasm, albeit at lesser intensities than the reference image of EGI-1. See Figure 27 































Figure 34: IF for MMP9 on TFK-1 
Top left panel- DAPI nuclear staining alone, top right panel- MMP9 visualized with Texas Red 
filter, bottom right panel- Merged image, Bottom left insert of 3 smaller squares showing the 
same image layout where primary antibody was omitted (control). Although used as the 
reference slide for best expression by microscopic assessment, hardly any staining is seen 
following image capture. Bottom left smaller square left blank (x63 magnification) 
Figure 35: IF for MMP9 on HuCCT-1 






























Figure 36: IF for MMP9 on Huh-28  
Strong cytosolic expression of MMP9 is seen in this instance. See Figure 34 legend for 
layout of panels (x63 magnification) 
 
Figure 37: IF for MMP9 on OZ 
Membranous staining (arrow) is noted on this occasion. See Figure 34 legend for layout of 






























Figure 38: IF for MMP9 on EGI-1 
 A punctate pattern of expression is observed within cytoplasm of tumour cells. See Figure 
34 legend for layout of panels (x63 magnification) 
 
Figure 39: IF for MMP9 on SkChA-1 
Small degrees of expression within tumour cytoplasm is seen. See Figure 34 legend for 










































Figure 40: IF for MMP9 on H69 
Membranous staining (arrow) is observed in this instance. See Figure 34 legend for layout of 
panels (x63 magnification) 
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Cell line NGAL MMP9 
EGI-1 +++ + 
HuCCT-1 ++ + 
Huh-28 - +++ 
OZ + ++ 
TFK-1 + + 
SkChA-1 - + 
H69 (normal) ++ ++ 
Table 11: Summary of expression of NGAL and MMP9 proteins detected 
on CCA cell lines by IF 
+++ denotes relatively strong expression, ++ moderate expression, + weak 
expression, - none detected.  
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3.2.7.2 Expression of NGAL and MMP9 in whole cell and membrane-
enriched lysates of CCA and normal cholangiocyte cell lines 
 
The objective of my Western blotting experiments was to identify if NGAL and 
MMP9 were present in whole cell lysates of CCA and H69 cell lines. Subsequently, 
these cell lines were assessed for membrane localization of NGAL using 
fractionated lysates.  
 
WB analysis utilising whole cell lysates revealed the presence of NGAL in all tested 
extra-hepatic CCA cell lines at its expected molecular weight (25kDa), and its near 
absence in the intra-hepatic cell line Huh-28 (Figure 41). EGI-I, TFK-1 and OZ 
showed relatively strong expression of NGAL on densitometric analysis of protein 
bands using ImageJ software. Densitometric data for H69 was obtained from 
separately run blots, and shows near absence of NGAL in this cell line (Figure 42). 
 
 
To determine the intracellular localisation of NGAL within the cells, membrane 
fractions were separated from cytoplasm as detailed in the Methods (section 
2.3.2.1). Western blotting of these fractions revealed a similar pattern of expression 
to that obtained with total cell lysates. A predominant expression of NGAL in the 
membrane fraction of the CCA cell lines EGI-1, TFK-1, OZ and HuCCT-1 was 
detected (Figure 43 and Figure 44). Once again, the intra-hepatic CCA cell line 
Huh-28 and the normal cholangiocyte cell line H69 did not express any NGAL. The 



































Figure 41: Western blot image showing NGAL protein (25kDa) expression in 
whole cell lysates of tested CCA cell lines.  
The absence of expression by the cell line Huh-28 is evident, whereas OZ shows the 
strongest expression (β-actin [42kDa] used as loading control and shows equal protein 
loading across lanes). 
 
Figure 42: Bar chart of relative NGAL expression by Western blotting in whole cell 
lysates of CCA and normal cholangiocyte H69 cell lines 
Intensities shown relative to loading control protein β-actin (given an intensity of 1). Near 
absent expression is observed for Huh-28 and H69 cell lines, whereas other CCA cell lines 
show varying degrees of NGAL expression (pooled data from 3 blots except for SkChA-1 




















































 Figure 44: Bar chart of relative NGAL expression by Western blotting in membrane 
enriched lysates of CCA and normal cholangiocyte H69 cell lines 
Intensities shown relative to loading control protein α-tubulin (given an intensity of 1), as 
derived from image in Figure 48. Near absent expression is once again seen in Huh-28 and 
H69 cell lines, whereas other CCA cell lines show varying degrees of NGAL expression. 
 
Figure 43: Western blot image demonstrating NGAL protein in membrane enriched 
lysates of CCA and H69 cell lines 
Preferential expression of NGAL (25kDa) in the membrane portion (‘M’) of fractionated cell 
lysates when compared to their corresponding cytoplasmic portion (‘C’). Expression is 
notably absent in Huh-28 and the normal cholangiocyte cell line H69 (α-tubulin [50kDa] used 
as loading control). 
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When whole cell CCA lysates were interrogated for MMP9, the 65kDa active 
isoform was identified in HuCCT-1, EGI-1, OZ and TFK-1, but not so in the case of 
Huh-28 and SkChA-1 (Figure 45).  I found that by visual assessment the expression 
of NGAL and MMP9 were proportional to each other across all lines (comparing 
Figures 41 and 45) except in the instance of HuCCT-1, which had weak NGAL 
expression but strong positivity for MMP9. 
 
A summary table of expression of NGAL and MMP9 is given below in Table 12.  
This compares the expression seen in both whole cell lysates (and membrane 
fractions for NGAL).  Large differences are also highlighted with regards to the 






























Figure 45: Western blot image showing MMP9 expression in whole lysates of CCA cell 
lines 
Blot performed on the upper sectioned half of the membrane used in Figure 41. Purified 
MMP9 positive control (92kDa) seen in the second vertical lane. The most prominent protein 
bands are seen at the 65kDa level (arrow) rather than 92kDa, corresponding to the active 
and latent forms of MMP9 respectively. TFK-1 and HuCCT-1 show the strongest positivity 
for the 65kDa isoform, with paucity of expression seen in Huh-28. Loading controls as 














 Table 12: Comparison of relative expression of NGAL and MMP9 in each cell 
line between WB and IF detection of proteins 
+++ denotes relatively high protein levels detected, ++ moderate levels, + low levels and – 



























to IF data 
EGI-1 ++ ++ Similar ++ Similar 
HuCCT-1 + +++ Similar ++ Similar 
Huh-28 - - Much lower - Much lower 
OZ ++ +++ Higher ++ Similar 
TFK-1 +++ ++ Higher +++ Higher 
SkChA-1 + N.D. Higher + Similar 
H69 - - Much lower N.D.  
 141 
3.2.7.3 Flow cytometry antibody optimization 
 
The purpose of FC analysis of CCA cell lines was as in the case of Western 
blotting, to determine the cell surface expression of NGAL and MMP9 towards 
ascertaining the suitability of these biomarkers for a targeting approach. 
Experiments were set up as detailed in the Methods chapter (section 2.3.3). 
 
Once samples were run, cell populations were segregated based on viability (7AAD 
positivity being the basis for exclusion) as shown in Figure 46, and histograms 
constructed for each dilution of antibody (Table 13), using the Diva software 
package v6  (Becton Dickinson, CA, USA). For the purposes of this optimization, 
SkChA-1 was used as its cells separated most easily of all CCA cell lines for 
sorting. The best deemed dilutions for both antibodies were taken forward for 
evaluation of other cell lines. 
 
As can be seen from the median fluorescence values in Figure 47, a primary 
antibody dilution of 1:25 offered the best distinction of the anti-NGAL antibody from 
the secondary fluorophore alone (Pacific Blue) and was therefore chosen as the 
optimal dilution for this antibody. In the case of MMP9 as shown in Figure 48, an 
optimal dilution of 1:25 again provided the best discrimination between the primary 
antibody and the Alexa Fluor 488 secondary.  Experiments using these optimized 
antibody dilutions were then repeated on other cell lines as illustrated in Figure 49 
and Figure 50. As is evident from the displayed data, I was not able to show a 
significant increase in median fluorescence intensity (which would reflect increased 
membrane expression) of anti-NGAL or  anti-MMP9 on these cell lines when 












Primary antibody amount 
in 50µl (final dilution in 
100µl volume) 




1 None None No 
2 None None Yes 
3 None Donkey anti-rabbit AlexaFluor 488 2ul (1:50) Yes 
4 None Goat anti-mouse Pacific Blue 2ul (1:50) Yes 
5 MMP9  4μl (1:25)  Donkey anti-rabbit AlexaFluor 488 2ul (1:50) Yes 
6 MMP9  2μl (1:50)  Donkey anti-rabbit AlexaFluor 488 2ul (1:50) Yes 
7 MMP9  1μl (1:100)  Donkey anti-rabbit AlexaFluor 488 2ul (1:50) Yes 
8 MMP9  0.5μl (1:200)  Donkey anti-rabbit AlexaFluor 488 2ul (1:50) Yes 
9 NGAL 4μl (1:25) Goat anti-mouse Pacific Blue 2ul (1:50) Yes 
10 NGAL 2μl (1:50) Goat anti-mouse Pacific Blue 2ul (1:50) Yes 
11 NGAL1μl (1:100) Goat anti-mouse Pacific Blue 2ul (1:50) Yes 
12 NGAL 0.5μl (1:200) Goat anti-mouse Pacific Blue 2ul (1:50) Yes 
 




Figure 46: Cell gating strategy for flow cytometry 
Left panel showing how the majority of the cell population is selected (shaded area). Right panel 
illustrating the result of selection of a predominantly 7AAD negative cell population. FSC and SSC 




Figure 47: Optimization of Abcam anti-NGAL antibody ab23477 on SkChA-1 cell line 
The optimal difference in median fluorescence values between the primary antibody and 
secondary fluorophore was seen at a primary antibody dilution of 1 in 25 
Figure 48: Optimization of Abcam anti-MMP9 antibody ab76003 on SkChA-1 cell line 
 Once again the optimal difference in median fluorescence values between the primary 
















Figure 49: FC analysis of NGAL surface expression on the CCA cell lines 
 HuCCT-1 (top panel), EGI-1 (middle panel) and the normal cholangiocyte cell line H69 
(bottom panel) are shown. In all 3 cell lines, no significant increase in median fluorescence 








Figure 50: FC analysis of MMP9 surface expression on the CCA cell lines 
 HuCCT-1 (top panel), EGI-1 (middle panel) and the normal cholangiocyte cell line H69 (bottom 
panel) are shown. Once again, no significant increase in median fluorescent counts is seen  with 
the use of the Abcam MMP9 antibody in comparison to the no-primary run. 
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(i.e. those with secondary fluorophore alone). Similarly, no appreciable difference in 
intensity was seen between CCA cell lines and control cholangiocytes (H69) either. 
This would perhaps be indicative of poor antibody performance, or inadequate 
optimization. At this stage, it was agreed that the alternative means of ascertaining 
cell surface expression of NGAL and MMP9 (WB and IF methods) would suffice, 
rather than devote more time to optimizing the FC protocol. 
 
3.2.8 ELISA of cell line supernatants shows evidence of 
extracellular secretion of NGAL by most CCA cell lines 
 
 
With studies investigating an association between serum NGAL and a diagnosis of 
CCA (Leelawat et al., 2011; Budzynska et al., 2013), I investigated whether NGAL 
is actively secreted by CCA cell lines. Clarifying this point would also have an 
impact on the success of a targeted delivery system, as this would indicate 
additional targeting could occur in the extra-cellular tumour milieu i.e. stroma. 
 
As illustrated in Figure 51, ELISA of 6 CCA cell line supernatants revealed the 
highest levels of NGAL secretion by OZ, with all other EH-CCA cell lines showing 
only half as much secretion of the marker. Of the IH-CCA cell lines, HuCCT-1 
showed positivity, whereas Huh-28 did not show any secretion. Notably, the normal 

















Figure 51: ELISA results showing NGAL concentrations in CCA and H69 cell 
culture supernatants 
Assay utilising 1/20 dilutions of CCA cell line supernatants, with the exception of 
Huh-28 and H69 (undiluted), and final NGAL concentrations determined by 
extrapolation to NGAL standard curve data. Near absent NGAL secretion into the 
extracellular compartment is seen with Huh-28 and H69 (pooled data from 3 runs 





The major thrust for investigating the 2 particular biomarkers highlighted in this 
study viz. NGAL and MMP9 as theragnostic biomarkers in CCA was the backdrop 
provided by recent proteomics work at our institution which identified these two 
molecules as being overexpressed in the bile of CCA patients (Farid, 2014). The 
next logical step to advance this work was to assess the expression of these 
markers in PH-CCA tissue. Accordingly, the experiments in this chapter were aimed 
to fulfil this objective and concurrently ascertain any prognostic effect of NGAL and 
MMP9 in PH-CCA. In addition, to explore the feasibility of adopting these molecules 
as theragnostic targets, I conducted experiments to determine if their expression 
was present on cell membranes and/or stroma, a pre-requisite for cellular targeting. 
(van Oosten et al., 2011). 
 
3.3.1 Tissue expression of NGAL and MMP9 
 
In comparison to MMP9, there is a marked paucity of literature on NGAL tissue 
expression in CCA, a point that is not entirely surprising given that the latter 
molecule was identified more than 2 decades after the discovery of MMP9 in 1967 
(Triebel et al., 1992; Brinckerhoff and Matrisian, 2002). There is only one other IHC 
study found pertaining to NGAL in CCA. This work from Thailand on a cohort of 24 
CCA specimens noted NGAL expression in all samples, and mostly cytosolic in 
cellular location. High levels of expression were observed in 75% of cases but no 
significant association with tumour differentiation, nodal status or metastasis was 
seen. Notably, non-tumorous tissue stained negative for the marker (Nuntagowat et 
al., 2010). Interestingly, the NGAL antibody used in this study (R&D Systems, MN) 
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was identical to that utilised in ours, albeit at dilutions much lower than what I 
optimised for use in the sections (1/1000 vs 1/100 respectively). Furthermore, they 
incubated sections overnight at 4°C and did not require addition of agents that block  
non-specific antibody binding such as Casein. Despite the differences observed in 
methodology and control tissue, some similarities were noted in this cohort of PH-
CCA patients. All of the specimens stained positive for NGAL and the median 
tumoural Histoscore was at the 82nd centile of the maximum. Important distinctions 
were clear too though - higher NGAL Histoscores were significantly associated with 
the occurrence of lymph nodal metastasis in my analysis and curiously, lower NGAL 
Histoscores were statistically linked with local recurrence (i.e. recurrent disease in 
the surgical resection bed). These two clinical parameters are both surrogates of 
aggressive disease and it is unclear why they are at odds with each other in terms 
of their association with NGAL Histoscore. A salient point observed in this series 
was the lack of an impact of nodal metastasis on survival, as elaborated in the next 
chapter. Nodal metastasis is a well established prognostic determinant in large 
series of PH-CCA (DeOliveira et al., 2007b; Nagino et al., 2013) and the modest 
numbers in this cohort most likely explains the lack of this finding in this series. One 
can only speculate that if NGAL has a prognostic effect in PH-CCA through an 
association with nodal metastasis, this may have been borne out with a larger 
series of patients. 
 
There is a larger body of data published on MMP9 tissue expression by IHC in CCA 
although initial reports deal solely with IH-CCA. A group from Japan noted in their 
series of 11 IH-CCA tissue specimens that MMP9 expression was present in 27% of 
cases, with stronger positivity seen in association with increased invasiveness. 
Localisation of the biomarker was in the cytosol and tumour stroma. No association 
with tumour differentiation was observed (Terada et al., 1996). Another Japanese 
group subsequently examined 37 cases of IH-CCA and found a MMP9 expression 
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rate of 43%. They found an increasing incidence of nodal metastasis with higher 
degrees of MMP9 expression, and this translated into a worse survival for these 
groups too (Shirabe et al., 1999). Understandably, a cause-effect relationship 
between MMP9 and survival cannot be drawn here and the prognostic observations 
are best explained by nodal status. In another report, Jo Chae and co-workers 
scrutinized 76 cases of IH-CCA from Korea for MMP9 tissue expression to find 67% 
of cases positive for the marker. These authors also assessed expression of TIMP-
1 and correlated all these findings to gross morphology of the tumour. In this 
fashion, it was observed that an imbalanced ratio of MMP9 to TIMP-1 expression 
was significantly more associated with MF and PI tumour morphology rather than IG 
subtype, and thus linked to more aggressive tumour behaviour (Jo Chae et al., 
2004).  
 
The profile of MMP9 expression in PH-CCA is less well studied in comparison to IH-
CCA. Turkish investigators assessed the expression of a group of MMPs in a cohort 
of various resected biliary cancers including PH-CCA. Of the latter subset of 8 
cases, MMP9 positivity was seen in all, and was significantly associated with peri-
neural invasion. No relation to tumour grade, vascular invasion or metastasis was 
noted (Kirimlioglu et al., 2009). A Chinese group led by Sang scrutinized the tissue 
expression of MMP9 in 49 cases of resected PH-CCA using software-assisted 
optical density measurements of positivity, and found it to be significant positive 
correlation with occurrence of nodal metastasis, and negative correlation with poor 
tumour differentiation. MMP9 expression was also found to be significantly higher in 
tumour tissue when compared to controls with benign biliary disease. No prognostic 
information was available in this report (Sang et al., 2013). A more recent study also 
from China also delved into the expression of this marker in resected PH-CCA 
specimens. Of the 58 cases examined, MMP9 positivity was found in 67% with a 
cytoplasmic predominance. Stromal expression of MMP9 was noted in all cases as 
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well, albeit at less intensity in comparison to tumour parenchyma. Importantly, 
although no significant statistical association was found between biomarker 
expression and any clinicopathological variable, overexpression of MMP9 was 
found to be an independent prognostic factor in poorer survival. The other 
independent prognosticator in their sample was nodal metastasis (Sun et al., 2014). 
There are some similarities in these two papers with my findings. I encountered 
100% positivity for MMP9 in this sample cohort. There was a predominant cytosolic 
staining although cell membrane and stromal positivity were seen uniformly across 
specimens too. A comparison of the primary antibodies used across these 3 PH-
CCA studies (including ours) shows that they were mutually different, with the 
streptavidin-biotin complex method being utilised for staining in those reports. In my 
group, no significant associations were seen between MMP9 tumour expression 
and any clinicopathological variable with the exception of local recurrence. As in the 
case of NGAL, I was surprised to learn that median lower MMP9 Histoscores were 
associated with this phenomenon, for reasons that are again unclear. I noted peri-
neural invasion in 89% of all cases, and this had no significant association with any 
biomarker Histoscore. 
 
The expression of NGAL and MMP9 in control liver tissue was an interesting 
observation, although seen at levels significantly less than corresponding tumour 
parenchyma. In the case of MMP9, existing literature is conflicting in this point, with 
studies noting both positivity (Kirimlioglu et al., 2009) and the absence of expression 
(Terada et al., 1996; Jo Chae et al., 2004) in normal liver tissue. PH-CCA is typically 
associated with jaundice at presentation and I wondered if this phenomenon could 
explain the NGAL positivity of matched control liver tissue in this series. Borkham-
Kamphorst and colleagues found that hepatocytes and bile ducts were induced into 
expressing NGAL in an experimental rodent model of liver injury caused by bile duct 
ligation (Borkham-Kamphorst et al., 2011). I was however unable to find a 
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significant correlation between pre-operative serum bilirubin and matched liver 
tissue NGAL Histoscore in this series. The use of avidin-biotin systems is well 
known to produce appreciable background signal in tissues rich in endogenous 
biotin such as liver, a phenomenon that is lessened with the substitution of avidin 
with streptavidin (Ramos-Vara, 2005). Though I used the ABC system in my NGAL 
staining protocol, it is difficult to say what degree of normal liver NGAL positivity is 
contributed to by true expression and/or methodology related factors. 
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3.3.2 NGAL as a theragnostic target 
 
Considering the results of my IHC experiments and realising that the existing 
literature on NGAL in PH-CCA was scant, I focused primarily on this biomarker in 
the next phase of experiments. Accordingly, the focus of my Western blotting and 
Immunofluorescence experiments was to determine if NGAL could be utilised as a 
theragnostic target. Central to this premise was establishing if the molecule is 
expressed on tumour cell membranes and extracellular space. My results, in 
particular the Western blotting analysis, conclusively showed that NGAL was 
expressed in the membrane fraction of most CCA cell lines, whilst being near 
absent in the normal cholangiocyte cell line H69. The findings of my ELISA analysis 
showed evidence of NGAL secretion into the cell culture supernatants of most CCA 
cell lines, but not H69. Based on this, I can surmise that NGAL is also secreted into 
the extracellular matrix by CCA tumour parenchyma, and this ties-in with my finding 
of stromal NGAL expression on IHC analysis. The results of my IF analysis showed 
some concordance with that obtained by WB, although two factors potentially 
confounded my interpretation. Firstly, cellular permeabilization was encountered 
during fixation, leading to cytoplasmic staining, which limited accurate assessment 
of membranous expression. Secondly, captured images did not necessarily reflect 
staining intensity as seen on direct visualization under the microscope, and this 
phenomenon was possibly related to image standardization by the related software. 
Accordingly, WB data was considered the more definitive of the two methods. 
The overall findings lead to the question whether NGAL is a valid theragnostic 
target in CCA. van Oosten and associates developed a unique weighted scoring 
system  that aimed to help determine the validity of candidate biomarkers as targets 







Whilst devised primarily as an aid to help select molecular markers for tumour 
imaging, the factors enumerated in the score are applicable to therapeutic targeting 
as well. As can be seen from this system, the highest weights are assigned to 
targets that are present on cell membranes and its vicinity viz. extracellular matrix. 
Using this score, the authors found that biomarkers with a score >18 had the 
potential for targeting use. In the context of colorectal cancers, biomarkers with the 
highest scores included EGFR and Epithelial Cell Adhesion Molecule (20 points 
each), Carcino-embyronic antigen (19 points) and interestingly MMPs (18 points), 
all of which incidentally have been used successfully for colorectal cancer imaging 
in experimental in vivo models. Applying the results of NGAL expression from this 
series to this scoring system viz. where I observed membranous and extracellular 
NGAL expression with diffuse up-regulation in tumour tissue to the order of 70-90% 
of samples, one can see that the provisional score generated by this biomarker is a 
Table 14: The TArget Selection Criteria (TASC) Scoring system for 
assessment of candidate biomarkers as theragnostic targets.  
T- expression in tumour, N- expression in normal tissue (From van Oosten 
et al. Selecting Potential Targetable Biomarkers for Imaging Purposes in 
Colorectal Cancer Using TArget Selection Criteria (TASC): A Novel Target 
Identification Tool. 
Transl Oncol. 2011; 4(2): 71–82; DOI:10.1593/tlo.10220 
Reproduced with permission from the publisher. 
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minimum of 17 (if I exclude points from T/N ratio >10 and success from prior in vivo 
imaging). As elaborated below, NGAL has already been used successfully for 
imaging in vivo, and therefore the net score would rise to a total of 19, making it a 
valid target biomarker. Understandably, this scoring system is nonetheless the first 
of its kind and needs further validation. 
Considering the important role that NGAL assumes in cancer regulation, it is not 
surprising that investigative efforts have already been made into targeting this 
molecule for theragnostic effects. One such report looked into the utility of a near-
infrared (NIR) dye labelled monoclonal antibody to NGAL as an imaging agent for 
pancreatic cancer using in vitro experiments and in vivo murine xenograft models 
(Wang et al., 2011).  Internalisation of antibody into cancer cells was noted in vitro.  
Although high tumour to background signal ratios were seen in vivo, specificity was 
poor with signal also being observed in other organs such as liver, kidneys and 
bladder.  A more recent study incorporated the use of anti-NGAL conjugated silica-
coated gold nanoshells in a murine pancreatic cancer xenograft model. These 
nanoparticles were doped with iron oxide and indocyanine green enabling their 
visualization with Magnetic Resonance Imaging and near-infrared (NIR) 
Fluorescence imaging respectively. The group thus demonstrated specific targeting 
of xenografts in this fashion, whilst showing a lack of cellular toxicity of these 
particles both in vitro and in vivo. Furthermore, NIR labelling facilitated successful 
photothermal therapy in vitro by the application of NIR laser at an appropriate 
wavelength (Chen et al., 2014). 
Despite these encouraging preliminary results, the varying and contrasting roles 
exhibited by NGAL in tissue homeostasis and cancer progression may be a cause 
for off-target effects and lack of therapeutic effectiveness when attempting to 
validate future inhibitors of this molecule. Clinical trials of MMP inhibitors have been 
fraught with similar shortcomings and the negative results of these trials have been 
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attributed in part to the high incidence of toxicity (mostly musculoskeletal) of MMP 
inhibitors which precluded the effective use of therapeutic dosages of these agents 
(Fingleton, 2008). My results indicate that in PH-CCA, hepatic parenchymal 
expression of NGAL can lead to unintended normal liver targeting with an anti-
NGAL strategy, although the extent to which this may occur is difficult to speculate, 
as tumour tissue harbours significantly more NGAL than matched normal liver 
parenchyma. One possible way to minimize the incidence of such effects is to 
confer an anti-NGAL targeting strategy further specificity using an additional homing 
target unique to tumour vascular endothelium, such as Vascular Endothelial Growth 
Factor (VEGF) and CD105 (Paauwe et al., 2013), which is the focus of my 
experiments in the next chapter. Nonetheless, the myriad roles played by NGAL in 
both normal physiology and cancer progression may well muddy the waters in the 
quest to use it as a specific theragnostic agent in this cancer. 
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4 Evaluation of vascular endothelial marker 
expression in PH-CCA and its applicability to a 





The aims of the work in this chapter were firstly to investigate the tissue expression 
of CD31, CD105 and VEGFR2 in PH-CCA and ascertain whether any of these 
endothelial markers had a prognostic impact in this cancer. This would indicate 
whether targeting any of these vascular receptors would potentially provide 
therapeutic benefit. Secondly, the potential of these markers as tumour vascular 
targeting ligands for microbubble-based imaging and therapeutic delivery was 
explored. If any of these markers were found to be overexpressed in CCA, they 
could be targeted to deliver theragnostic payloads, independent of any prognostic 




The expression of 3 vascular endothelial markers viz. CD31, CD105 and VEGFR2 
was assessed in tissue samples of 54 patients who underwent resection of PH-CCA 
from 2000 to 2010. As described in the Methodology section, measurement of 
micro-vessel density (MVD) using the ‘Hot-spot’ technique was employed for this 
purpose. Since CD31 is known to be a pan-endothelial marker (Pusztaszeri et al., 
2006) its expression was used as the denominator against which the other 2 
biomarkers were compared.  
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4.2.1 CD31 and CD105 are consistently expressed in PH-CCA 
tissue and control liver parenchyma but VEGFR2 less so 
 
 
IHC was performed following optimization of antibodies as shown in Table 15. The 
staining patterns of CD31, CD105 and VEGFR2 in PH-CCA are demonstrated in 
Figure 52 and Figure 53. CD31 highlighted microvessels in all tested tumour 
sections with minimal background staining. The expression of CD105 in contrast 
showed more variability. As shown in Figure 52, CD105 showed a staining profile 
similar to that seen with CD31, but in other instances, a substantial amount of 
background stromal expression was visualized as well, as shown in Figure 53. As 
was the case for CD31, all sections showed positivity to CD105. When evaluating 
stromal CD105 staining, this was found to be absent to mild in 39%, and moderate 
to strong in 61% of cases. 
 
The evaluation of VEGFR2 MVD however revealed that this marker was largely 
absent in the assessed ‘hot-spots’. Interestingly, many sections deemed negative 
for VEGFR2 using the hot-spot criteria showed evidence of expression in other 
regions of the same sections, as demonstrated in Figure 54. In light of this finding, 
VEGFR2 expression was also categorised as present or absent, based on 
assessment of the whole section rather than just hotspots,. Using this approach, 
VEGFR2 was found to be absent from 26 (48%) cases. 
 
In the instance of control liver parenchyma, CD31 was found to uniformly stain 
hepatic sinusoids, and vascular endothelium within portal triads, as shown in Figure 
55 and Figure 56. CD105 also showed evidence of expression in both sinusoids 
and portal tracts in varying intensities, across all cases, albeit in general less than 







Table 15: IHC antibody optimization strategies for vascular endothelial markers used 































Proteinase K 1/20 
1 hour RT 
Overnight 
4°C 

























1 hour RT 
Overnight 
4°C 
None, 1/200, 1hr 
RT 
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Figure 52: Consecutive sections of PH-CCA stained for CD31, CD105 and VEGFR2 
 CD31(top panel) is seen to have the highest MVD, whereas VEGFR2 (bottom panel) is 
notable by its lack of expression. CD105 (middle panel) shows a similar pattern of 
expression to CD31 but with less vessel density 
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Figure 53: Consecutive sections of PH-CCA stained for CD31, CD105 and VEGFR2 
 In this instance, a significant degree of stromal (long arrow) and parenchyma (short arrow) 
staining is observed for CD105 (middle panel), whilst absent expression is noted with 



























Figure 55: The expression of vascular endothelial markers CD31 and CD105 in 
normal liver parenchyma 
CD31 staining (left panel) and CD105 (right panel) staining seen in consecutive sections 
of normal liver parenchyma and demonstrates the affinity of both these markers for 
hepatic sinusoids (short arrows) and vessels in the portal triad (long arrows). 
Figure 54: Evidence of VEGFR2 expression in an area outside a 
designated hotspot 
 This image was taken from the same section shown in Figure 52 and 
demonstrates VEGFR2 positivity (short arrows) in a case that would 































Figure 56: The expression of vascular endothelial markers CD31, CD105 and VEGFR2 
in consecutive sections of control liver parenchyma 
Evidence of CD31 staining (top panel) in hepatic sinusoids (short arrow) and vascular 
structures in the portal triad (long arrow) is demonstrated. The degree of such staining for 
CD105 (middle panel) in this instance is seen to be less, whereas no expression is seen 
with VEGFR2 (bottom panel). 
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4.2.2 Comparison of Micro-vessel density scores of all three 
endothelial markers in PH-CCA shows CD31 to have the 
highest expression and VEGFR2 the least 
 
Figure 57 displays the MVD scores of all 3 endothelial markers in comparison. As 
can be seen, CD31 showed the highest levels of expression, whereas median 
CD105 MVD scores were just under half that (45 and 21.3 respectively). VEGFR2 
showed negligible levels of positivity (median MVD score of 0.67), although when 
assessing whole sections (and not only hot spots), VEGFR2 positivity was seen in 
52% of the group. A moderate degree of correlation between MVD scores of CD31 
and CD105 was seen as demonstrated in Figure 58. 
 
In the case of matched control liver parenchyma, assessment was purely qualitative 
as MVD scoring was not feasible in light of extensive sinusoidal staining. 
 
As described in the Methods section, inter-observer correlations were assessed for 
MVD scores between 2 scorers (AN and EV) for the first third of cases. These 
results are displayed in Figure 59. The degree of agreement between scorers for 
CD31 and VEGFR2 was good (Spearman r= 0.53 and 0.60 respectively). In the 
case of CD105, inter-observer correlation was poor initially (r<0.4; data not shown) 
and the scorers re-convened to assess MVD scores again. It is interesting to note 
that in this instance, the correlation was excellent (r=0.93) and was due to the 
scorers discussing and agreeing upfront which areas of the section were to be 
labelled ‘hot-spots’. Once this was decided, MVD scores were calculated 






































Figure 57: Scatter plot representation of MVD scores of all 3 endothelial markers in 
PH-CCA 
CD31 showed the highest MVD scores, whereas the majority of sections expressed very 
poor levels of VEGFR2 (horizontal longer bars indicating median and shorter bars inter-
quartile range) 
Figure 58: Scatter plot showing correlation between CD31 and CD105 MVD scores in 
PH-CCA 
Good correlation between these 2 markers is observed in our cohort. Line of best fit drawn 





















































Figure 59: Inter-observer correlations for MVD assessment between 2 scorers 
(AN and EV) for all 3 endothelial markers 
Plotted data and line of best fit shown in all graphs. Top panel (n=18) showing data 
for CD31 (Spearman r=0.53, p=0.022), middle panel (n=18) exhibiting data for 
CD105 (Spearman r=0.93, p<0.0001) and bottom panel (n=17) showing data for 
VEGFR2 (Spearman r=0.60, p=0.011). 
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4.2.3 Tissue expression of CD105 assumes prognostic 
significance in PH-CCA 
 
The characteristics of the study population are summarised in the previous chapter 
(Table 9). The results of univariate analysis of endothelial marker expression 
against clinicopathological patient variables are shown in Table 16. The salient 
points here are that lower median CD31 MVD scores were associated with 
increased rates of local recurrence of tumour (i.e. within the surgical bed), whereas 
in the case of VEGFR2, presence of its expression was associated with the 
development of metastases. It is noteworthy that CD105 MVD scores bore no 
significant statistical association with any of the analysed variables 
 
 
The median OS of the entire cohort of patients was 22.3 (IQR 10.8 - 39.7) months, 
whilst the group had a median DFS of 13.8 (4.8 – 33.4) months.  
 
As elaborated in the Methods section, MVD scores for CD31 and CD105 were 
dichotomised at an optimal value for the purposes of survival analysis. This cut-off 
value was determined separately for each marker so as to generate the maximal 
statistical significance on log-rank (univariate) analysis.  
 
Figure 60 and Figure 61 display the Kaplan-Meier survival curves for CD31 and 
CD105 at the optimal MVD cut-offs (68 and 31 respectively). As can be seen from 
this data, higher degrees of expression of both these endothelial markers showed 
significant association with poorer OS. The full results of survival analysis for 
analysed variables are shown in Table 17. Median OS in those patients with CD105 
MVD>31 was 12 months versus 31 months in the group with CD105 MVD<31. 
Neither CD31 nor CD105 MVD was significantly associated with DFS, and VEGFR2 









Table 16: Comparison of MVD scores of all three endothelial markers and VEGFR2 positivity against clinicopathological patient variables 
Significant p values highlighted in bold and italics. Mann-Whitney U tests used for continuous variables and Fisher’s exact test for dichotomous 
data. Local recurrence defined as recurrent disease in surgical bed. Progressive disease indicating local recurrence and/or metastasis (MVD: 
Micro-vessel density, IQR: Inter-quartile range) 
 
 













Age (years) at 
diagnosis 








>58 27 50 46(40-64) 24(17-33) 1.3(0-3.0) 15 12 
Gender 








Female 23 43 54(40-64) 22(14-31) 0.3(0-3.0) 10 13 
Tumour size 
(mm) 








>30 28 54 45(37-64) 24(14-32) 0.6(0-3.0) 14 14 
Histological 
grade 




















No 18 35 43(35-54) 21(18-28) 1.0(0-2.4) 10 8 
Nodal 
metastases 








No 25 46 41(29-58) 24(18-31) 1.0(0.3.0) 13 16 












T3/T4 23 43 45(40-61) 23(14-30) 0.3(0-2.4) 11 12 
Resection 
Margins 








R1(positive) 33 61 41(35-63) 21(14-31) 1.3(0-3.3) 20 13 
Local 
recurrence 








No 49 91 48(39-64) 20(15-32) 0.6(0-3.0) 25 24 
Metastasis 








No 29 54 48(40-62) 20(12-33) 0(0-2.0) 11 18 
Progressive 
disease 




































































Figure 60: Kaplan Meier survival curves for CD31 MVD cut-off at 68 
 Curves demonstrating a significant difference in survival between patient 
groups at this MVD cut-off (p= 0.042, log-rank test). Table below graph 
indicating numbers at risk at corresponding time points. 
Figure 61: Kaplan Meier survival curves for CD105 MVD cut-off at 31 
 Curves demonstrating a significant difference in survival between patient 
groups at this MVD cut-off (p= 0.002, log-rank test). Table below graph 








Table 17: Univariate (Log -rank tests) and multivariate (Cox Regression) analysis of factors predictive of survival in this cohort of PH-CCA 
Factors significant on univariate analysis were entered into the Cox Regression model. Significant p values highlighted in bold and italicized (OS: overall 
survival, DFS: disease-free survival, HR: Hazard ratio, CI: Confidence interval, MVD: micro-vessel density 
 
Univariate analysis Multivariate analysis 
OS DFS OS DFS 
Variable n 
Median survival    
in months 
HR (95% CI) p value 
Median survival  
in months 
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value 
CD31   
MVD 
<68 44 31.4 
2.2(1.0-4.9) 0.042 
31.2 
1.8(0.7-4.5) 0.212 0.2 (0.03-1.5) 0.132   
>68 10 16.7 18.3 
CD105 
MVD 
<31 13 31.4 
3.2(1.5-6.8) 0.002 
23.1 
1.7(0.6-4.6) 0.292 12.5(1.9-79.9) 0.007  
>31 40 12.2 13.6 
VEGFR2 
positivity 
Yes 28 30.8 
 0.646 
18.3 
 0.236   
No 26 24.6 23.2 
Nodal 
metastasis 
Yes 29 21.7 
 0.085 
17.3 
 0.634     
No 25 32.6 31.2 
Tumour 
size 
<48mm 40 32.0 
4.1(1.6-10.6) 0.002 
23.2 
3.3(1.2-9.5) 0.019 5.0 (1.9-13.4) 0.001 2.6 (0.9-7.7) 0.071 
>48mm 12 12.7 11.2 
Tumour 
stage 
T1/T2 31 31.4 
 0.277 
31.2 
  0.530     
T3/T4 23 23.8 18.7 
Tumour 
grade 
Grade 1 27 25.9 
 0.220 
23.2 
 0.556     
Grade 2/3 27 24.6 18.7 
Vascular 
invasion 
Yes 33 24.6 
 0.177 
18.3 
 0.650     
No 18 32.0 32.9 
Resection 
margin 
Positive 33 23.7 
 0.203 
18.3 
 0.032   2.1 (0.9-5.2) 0.080 
Negative 21 37.0 51.2 
AJCC stage 
II 15 37.3 
 0.116 
32.9  
0.504   
III/IV 39 22.8 18.3  
Local 
Recurrence 
Yes 5 33.9 
 0.568 
 
 N/A   
No 49 23.8  
Metastasis 
Yes 25 24.6 
 0.154 
 
 N/A     




Other factors that showed statistical significance included primary tumour size 
>48mm (for both poorer OS and DFS) and resection margin positivity (for worse 
DFS, but not OS). Factors significant by univariate survival analysis were entered 
into a multivariate (Cox proportional hazards) regression model. This revealed that 
CD105 MVD >31 and primary tumour size >48mm were independently associated 
with poorer OS in this cohort of PH-CCA patients. CD31 expression lost the 
statistical significance it had with OS on univariate analysis when put through this 
model. 
 
4.2.4 The murine endothelial cell line SVR shows surface 
expression of CD105 on Immunofluorescence studies 
 
In order to establish a targeted delivery system in CCA, it is necessary to ensure a 
systemically administered payload (such as that delivered by microbubbles) can 
home in to tumour regions. Subsequent to this would be the successful crossing of 
tumour capillary vascular endothelium by these payloads into the stromal/interstitial 
compartment, although this aspect was not investigated in this study. With a view 
towards translation of this concept into a murine model, I initially assessed whether 
CD105 could be used as an ‘anchoring’ target on murine vascular endothelium. The 
first step in this process was to establish that the murine endothelial cell line SVR 
expressed CD105, and this was done using IF studies as shown in Figure 62. 
















































Figure 62: Immunofluorescence images of CD105 staining on the SVR cell line 
The middle-right image showing a composite of the top-left (CD105 antibody alone 
visualized with the Texas Red filter), top-right (showing nuclear staining alone), and middle-
left (phase contrast) images. A clear pattern of membranous expression of CD105 is seen. 
The bottom-left image illustrates the lack of expression when the primary antibody is 
omitted, and the bottom right image showing nuclear staining alone in this no-primary 
section. 
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4.2.5 In vitro flow assays using CD105 coated microbubbles show 
significant binding to SVR cells 
 
Flow assays were set up as detailed in the Methods chapter (section 2.3.5). 
Experiments were performed using two preparations of MBs viz. those that are 
commercially available (Bracco) and those generated in-house. Each preparation 
was used in separate experiments. MB binding was expressed in ratios between 
MBs in contact with cells and total number of SVR cells per assessed field. 
CD105 and its isotype control facilitated binding of MBs to SVR cell line is 
demonstrated in Figure 63. MBs are identified in these images through their 
refractile, bi-layered, rounded appearance. Figure 64 shows the scatterplot data for 
MB binding to SVR cells. Both Microfluidics and Micromarker MBs showed 
significantly higher levels of binding to SVR cells when bound to CD105 than its 























































Figure 63: Inverted light microscopy examination of SVR cell lines as part of flow 
assay experiments  
Left image taken following flow of CD105 antibody bound MB and the right image following 
flow of isotype control antibody. Bound MBs (long arrows) and unbound MBs (short arrow) 
are demonstrated. As can be observed, the number of bound MBs is relatively less in the 
isotype control image (x40 magnification). 
Figure 64: Scatterplot data summarising the results of flow assay experiments using 
CD105 and isotype control antibody-bound MBs.  
Top image (n=11) showing the results of use of Microfluidics MBs and bottom two images 
(both n=5) that from Micromarker MBs. The use of CD105-bound Microfluidics MBs revealed 
significantly higher binding of SVR cells to that of isotype-control bound MBs, at an antibody 
concentration of 0.05µg/ml (p=0.020). CD105-bound Micromarker MBs also showed the same 
behaviour at an antibody concentration of 0.1µg per 10
7
 MBs (p=0.016) as displayed in the 
bottom left image. At a lower antibody concentration of 0.05µg per 10
7
 MBs, this difference 
was not significant (NS), as shown in the bottom right image (p=0.117). Data expressed as 
median with interquartile ranges. Mann-Whitney U tests used for comparisons. 
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4.2.6 CD105-bound Micromarker Microbubbles target EGI-1 and 
TFK-1 xenograft endothelium in significantly higher 
amounts compared to isotype control in a murine model 
 
Of the 6 available CCA cell lines, none except TFK-1, EGI-1 and OZ generated any 
visible subcutaneous tumour growth following inoculation in CD1or Balb/c mice. As 
shown in Figure 65, EGI-1 and TFK-1 grew better tumour volume xenografts (Figure 
66) although all showed an occasional tendency for spontaneous xenograft 
regression. For my experiments, EGI-1 and TFK-1 were finally selected for in-vivo 
MB testing. These cell lines were then re-established as subcutaneous xenografts 
in CD1 nude mice, and in-vivo testing of MB binding assessed as detailed in section 
2.4.2 of the Methods chapter. The degree of binding of MBs to tumour endothelium 
was quantified by means of the subtracted molecular signal, which denotes the 
difference in signal observed between bound and flowing MBs together and flowing 
MBs alone (Figure 67). These results are summarised in Figure 68 and show that in 
5 out of the 6 TFK-1 xenografts as well as all 4 EGI-1 xenografts, the subtracted 
molecular signal was significantly higher in the CD105 MB group in comparison to 
the isotype control MB group. This therefore indicates that TFK-1 and EGI-1 
xenograft vasculature can be targeted using CD105 directed MBs, and mirrors the 
findings I obtained from  in vitro tests using CD105 labelled MBs. 
 
4.2.7 CCA xenografts show peri-tumoural vasculature that 
expresses CD105 
 
Following completion of the in vivo CD105-MB experiments, animals were sacrificed 
and xenografts harvested, formalin fixed and paraffin embedded for CD105 IHC 
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examination. As shown in Figure 69, peri-tumoural vessels showed positivity for 




Figure 65: Xenograft growth curves for indicated CCA cell 
lines  
Each line represents one mouse. Black lines showing data for 












Figure 66: H&E staining of TFK-1 and EGI-1 xenografts. 
TFK-1 on left an EGI-1 on right (both x10 magnification). Xenografts are seen as 





Figure 67: In vivo US imaging of TFK-1 xenograft following intravenous administration of Micromarker MBs and destructive US pulse, with associated 
subtracted molecular signal data 
Top left image showing US appearance of tumour following administration of MBs bound to isotype-control antibodies (manifested as green coloured signal within 
tumour, reflective of both flowing and bound MBs); top middle image showing same section following application of destructive US pulse (green signal now 
indicative of only flowing MBs). Top right image demonstrating the difference in molecular signal intensity prior to (left of vertical red line) and after (right of 
vertical red line) application of destructive US pulse. Images in bottom panel showing corresponding findings following administration of CD105-bound MBs. A 























































Figure 68: Depiction of binding of CD105 labelled Micromarker MBs versus isotype 
control MBs 
A series of 6 measurements (for cell line TFK-1) and 4 measurements (for cell line EGI-1) used 
in the murine heterotopic xenograft model of CCA. A significant difference in subtracted 
molecular signal (indicative of the degree of MB binding to tumour endothelium) when 
subjected to a destructive US pulse is seen in both instances (TFK-1 p=0.028 and EGI-1 
p=0.043) between CD105 and its isotype control. Wilcoxon sign rank tests used for matched 
data comparisons. 
 
Figure 69: Image showing evidence of CD105 positive 
vessels at the periphery of EGI-1 xenograft tissue 
CD105 positive murine vessels (arrow) are seen forming a rim 
around the subcutaneous xenograft. The latter was harvested 
following completion of in vivo CD105-MB binding experiments. 
Evidence of stromal CD105 expression is also noted within the 






The targeting of a biomarker that is overexpressed in cancer tissue for theragnostic 
use by systemic administration of an appropriate molecule or payload is an 
attractive concept. However, the notion is simplistic when compared to its 
realisation and the efficacy of such an approach in practice is suboptimal. The bio-
distribution and pharmacodynamic characteristics of a given theragnostic molecule 
can prevent its effective localization to target tissue, with accumulation and/or 
metabolic degradation in normal tissues instead (Scott et al., 2012), leading to 
markedly diminished targeting efficacy. Even when considering the added 
physicochemical attributes of NPs that enable passive tumour targeting through 
EPR, NP localization to tumour is only to the order of approximately 5% when 
simply administered as intravenous injection (Bae and Park, 2011). 
 
A method of improving delivery of systemic payloads to tumour tissue is to target 
tumour vascular endothelium as a preliminary step. Capillary vascular endothelium 
is the first physical barrier between the bloodstream and tumour interstitium, and 
this must be crossed in order for theragnostic particles to exert their actions. The 
concept of a delivery vehicle that can both carry theragnostic payloads and bind 
tumour endothelium is fulfilled by MB systems. MBs can be functionalized through 
the addition of ligands to its surface that allow endothelial binding of the former. 
Accordingly, this would enable a higher proportion of the payload to be optimally 
retained in tumour vasculature, prior to its release into tumour tissue. Such a 
system also serves to lessen exposure of payloads to processes that can result 
from continued circulation such as metabolism or immune-mediated neutralization, 
although other methods also exist to mitigate these effects such as payload PEG-
ylation or inclusion in liposomal formulations.    
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Identifying the optimal endothelial marker for targeting in CCA was the first focus of 
my efforts in this chapter. An ideal endothelial target would be expressed 
exclusively or predominantly in tumour blood vessels, although no currently known 
marker fulfils this property. Nonetheless, as a body of literature pointed out that 
CD105 and VEGFR2 are expressed in proliferating endothelium (Dallas et al., 2008; 
Seon et al., 2011) as should be seen in cancer tissue, I investigated these markers 
in further detail.  
 
CD31 was utilised primarily as a reference endothelial marker in my IHC work 
although interestingly, its impact in CCA prognosis has also been analysed 
previously. Thelen and associates examined the impact of CD31 MVD on disease 
prognosis in a series of 60 patients who underwent resection of PH-CCA. The mean 
MVD was found to be 28 (range 4 - 71), whereas cases were segregated into high 
and low MVD categories based on a value of 20. In this fashion, high MVD tumours 
were found to be significantly linked to higher risk of nodal involvement and local 
recurrence but not systemic metastasis, whilst on Cox regression analysis high 
MVD, along with nodal metastasis were independent predictors of adverse OS 
(Thelen et al., 2008). In contrast, I observed a median CD31 MVD of 45 (range 8-
98) in this series, whilst a significantly lower CD31 MVD was associated with local 
recurrence. The expression of CD31 though significantly associated with OS on 
univariate analysis had no prognostic impact on this cohort in the Cox regression 
model. In a subsequent paper, Thelen and co-workers again analysed CD31 MVD 
in a group of 114 resected IH-CCA patients and noted a mean MVD of 13 (range 2-
44). A significant association of high MVD (defined as a count above the mean of 
13) was found with primary tumour stage, positive surgical margins, peri-neural 
infiltration and higher rates of recurrence.  Multivariate analysis revealed a high 
MVD as a prognostic factor for poorer OS.(Thelen et al., 2010). 
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When considering CD105, there are currently no sizeable published series in the 
English language that delve into the tissue expression of this marker in CCA. One 
report investigating the influence of hypoxia inducible factor-1 in the response to 
photodynamic therapy in PH-CCA using an in vitro model also evaluated the tissue 
expression of CD105 in this cancer, in the marker’s capacity as a hypoxia related 
protein. Of the two tissue samples analysed, dense staining of microvessels in 
tumour stroma was noted, and in contrast, no expression was seen in tumour 
parenchyma (Weijer et al., 2016). Whilst I also observed a high rate of stromal 
positivity in our cohort, tumour parenchyma was found to express CD105 as well in 
many of the cases. In addition, this series is the first of its kind to scrutinize the 
expression and prognostic impact of CD105 MVD in PH-CCA, and although this 
bore no significant statistical association with any patient factors, I was able to show 
that a MVD >31 was associated with significantly poorer OS.  
 
The results of my VEGFR2 expression analysis were also noteworthy. I 
encountered very low MVD scores, with many samples showing no presence of the 
marker. Accordingly, I dichotomised its expression into positive and negative, with 
the former group comprising 52% of the total. The only factor significantly 
associated with VEGFR2 positivity was the occurrence of metastasis, although the 
marker carried no association with OS or DFS. Although various reports have 
examined the expression of various forms of VEGF and its impact on CCA, studies 
looking into VEGFR2 are scant, and assess tumoural expression as opposed to 
endothelial staining. Sang et al looked into the expression of VEGFR2 by IHC in 49 
resected cases of PH-CCA and analysed positivity by means of computer-aided 
optical density measurements. They found mean VEGFR2 optical density to be 
significantly higher in those cases with nodal metastasis and somewhat 
paradoxically tumours with low to moderate differentiation, whilst these values were 
also higher in tumour tissue compared to benign biliary pathology. No data on the 
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effect of expression on survival was provided (Sang et al., 2013). Peng and 
associates during their study into the effects of Apatinib (a VEGFR2 inhibitor) on 
CCA cell lines also evaluated the expression of VEGFR2 in 104 cases of IH-CCA. 
Once again, tumoural expression was assessed as opposed to MVD, and positivity 
was noted in 60% of samples. Expression was found on cell membranes, cytosol 
and nuclei of tumour cells (Peng et al., 2016). Although specific inhibitors of 
VEGFR2 have not yet reached clinical translation, clinical trial data does exist on 
the use of the VEGF-A inhibitor Bevacizumab in advanced biliary tract cancers. Two 
phase-2 human trials have demonstrated modest activity of this drug against tumour 
with acceptable rate of adverse events, when used in combination with other 
chemotherapeutic or anti-EGFR agents (Lubner et al., 2010; Zhu et al., 2010). 
Nonetheless, my data in conjunction with that of others points to the heterogeneity 
of expression of molecular targets in CCA worldwide, and could explain the differing 
rates of tumour response to targeted therapies.   
 
As is apparent in the literature on the use of MVD in various cancers, disparate 
results are often seen in the impact of MVD on disease prognosis, with both high 
and low MVD being shown as significantly associated with OS. Although differences 
in methodology and endothelial markers used can sometimes account for these 
observations, most of these findings are a true reflection of the varied influence of 
MVD on disease progression. MVD does not mirror the angiogenic activity of a 
tumour per se but rather indicates its metabolic burden. Thus even in the presence 
of much angiogenic activity or aggressive cancer biology, MVD can be low in those 
tumours with increased hypoxic tolerance, and as such should not be used to 
determine which patients might benefit from anti-angiogenic treatments (Hlatky et 
al., 2002; Nico et al., 2008). As my findings suggest, the use CD31-based hotspots 
for MVD measurements did not necessarily highlight the most active area of neo-
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angiogenesis, as its expression is limited to established, mature endothelium. Both 
CD105 and VEGFR2 stained vessels that were not picked up by CD31. 
 
In addition to the prognostic effect that was demonstrated with CD105 MVD in this 
series, an equally pertinent observation I made was the expression of CD105 in 
hepatic sinusoidal endothelium. Similar findings have been noted in related 
literature, with CD105 expression observed mostly in the outflow region of the 
sinusoids, adjacent to the terminal hepatic vein (Theuerkauf et al., 2001; Yu et al., 
2007). Previous authors have also documented the expression of CD105 in both 
tumour and non-tumour bearing liver parenchyma (Ho et al., 2005; Minhajat et al., 
2006; Nakamura, 2009) and put forth the view that in peri-tumoural areas its 
presence is perhaps indicative of a field change that predisposes to tumour 
progression (Nakamura, 2009). Nonetheless, my finding bears relevance in the 
development of a targeted particle directed against this molecule as off-target 
effects on hepatocytes would not be surprising under these circumstances. The use 
of focused high-frequency US to improve specificity of payload targeting by MBs 
can in theory ameliorate such lateral effects but in the case of tumours like PH-CCA 
that are intimately associated with the liver, the degree of specificity gained by US-
aided MB sonoporation may be modest.             
 
The first step towards exploring the feasibility of targeting tumour endothelium in an 
in vivo model was to verify CD105 expression in murine endothelial cells, as 
xenografts are supplied by native vessels. Accordingly, my IF experiments 
confirmed CD105 positivity on the surface of the murine SVR endothelial cell line. 
This finding gave us the background required to assess the binding of CD105 ligand 
coated MBs to SVR cells in an in vitro flow assay model aimed to simulate capillary 
blood flow. This demonstrated that CD105-MBs could bind SVR cells appreciably 
more than isotype control MBs under conditions of simulated capillary flow. Finally, 
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the results of my murine in vivo MB experiments revealed that these intravascular 
agents when functionalised with surface CD105 ligands were able to bind CCA 
xenograft endothelium at significantly higher levels than that seen with MBs with 
isotype control. The use of CD105-conjugated MBs has been reported in the 
literature previously. Korpanty and associates demonstrated using in vitro 
experiments that MBs could be functionalised with biotinylated CD105 by 
incorporating avidin into the MB shell. Using tagged fluorophores and in conditions 
of stasis (rather than flow), they were then able to demonstrate that these targeted 
MBs bound to endothelial cell cultures at significantly higher amounts than control 
MBs, but not so for fibroblast cultures (Korpanty et al., 2005). The same group in a 
subsequent paper showed that MBs conjugated with CD105 and VEGFR2 ligands 
were able to bind pancreatic cancer xenograft vasculature significantly better than 
control MBs, using contrast US imaging in a murine model. Mice treated with 
Gemcitabine when compared to control showed a significant reduction in vascularity 
as demonstrated with CD105-MB (Korpanty et al., 2007). In more recent work, Zhou 
and colleagues successfully transfected breast cancer xenografts in mice with the 
endostatin gene using CD105 conjugated MBs through the means of US directed 
MB destruction. Xenografts successfully transfected in this fashion showed 
evidence of significantly higher levels of endostatin expression when compared to 
control, along with significant reduction in tumour volumes  (Zhou et al., 2015). 
 
My results are therefore the first described use of CD105 functionalised commercial 
MBs in a model of CCA. Through the use of in vitro and in vivo models, I have 
shown that these MBs bind SVR cells significantly more than isotype control MBs 
under similar conditions. Willman and co-workers performed similar in vivo US 
experiments using micromarker MBs conjugated to VEGFR2 on heterotopic murine 
angiosarcoma and rat-glioma tumours. Their results showed significant rise in video 
signal from VEGFR2-conjugated MBs in comparison to control MBs, indicating that 
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VEGFR2 expression in vessels supplying these subcutaneous tumours could be 
non-invasively assessed (Willmann et al., 2008). Whilst I did not assess the efficacy 
of a targeted payload delivery to CCA tissue, the literature reveals that such MBs 
can be conjugated with a theragnostic particle to effect diagnosis and treatment. 
The degree of off-target effects to normal liver tissue is unknown at present, and is 
the potential Achilles heel in a targeted delivery system that relies on a homing 
biomarker that is expressed in both tumour and liver sinusoidal endothelium. 
 
The success of a novel anti-cancer treatment paradigm in an animal model does not 
indicate its imminent success in human trials (van der Worp et al., 2010). However, 
even with the use of ectopic tumour sites, the use of mouse models of disease may 
reliably inform future human studies especially when variables such as the in vivo 
behaviour and kinetics of a candidate molecule are being investigated (Kerbel, 
2003). In the case of CD105, phase-I human trials have already been conducted on 
the backdrop of promising anti-angiogenic effects seen in animal experiments. The 
IgG1 chimeric monoclonal antibody to CD105 (TRC105) when administered as an 
intravenous preparation was found to be well tolerated in a group of 50 patients with 
various refractory advanced solid cancers, with adverse events noted in 18% of the 
group, including hypo-proliferative anaemia. Stable disease at 2 months was noted 
in 47% of 45 evaluated patients, which dropped down to 14% of 44 patients at 4 
months (Rosen et al., 2012). The agent has also been similarly evaluated in 
combination with Bevacizumab in another phase-I trial, with a good safety profile 
and evidence of anti-tumour activity seen in those patients refractory to VEGF 
inhibitor therapy (Gordon et al., 2014). At present, there are several on-going 
phase-II trials using TRC105 in combination with other agents in a variety of solid 
cancers (Tracon Pharma). A recent relevant phase-II study of TRC105 in advanced 
HCC patients who had progressed on Sorafenib also posted interesting 
observations despite its negative result. The trial accrued only 11 patients and the 
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overall rate of disease progression did not allow completion of all stages of the 
study.  Nonetheless, durable anti-cancer activity was evident in only one patient and 
treatment tolerability overall was considered good. What can be inferred from these 
phase-I and II studies is primarily that anti-CD105 intravenous therapy has a good 
safety profile, and in particular no adverse events in relation to the liver were 
reported. One can postulate however that with a successful targeted approach 
using CD105 to CCA, both treatment efficacy and the rate of liver-related adverse 





This body of work set about to answer two pertinent questions in the context of the 
treatment of peri-hilar cholangiocarcinoma. The first objective was to establish 
whether NGAL and MMP9 had any prognostic impact in this malignancy and if 
these biomarkers possessed properties that enabled their targeting to diagnostic or 
therapeutic effect. I showed that whilst NGAL had a statistically significant 
association with lymph nodal metastasis, neither biomarker had a significant 
bearing on survival in this cohort. This could be reflective of an inadequate sample 
size that was not powerful enough to detect any such effects. Nonetheless, NGAL 
was also found to be expressed on the cell surface and tumour stroma, both of 
which are qualities that make it suitable for a targeting approach. 
 
Secondly, I interrogated the vascular endothelial markers CD31, CD105 and 
VEGFR2 (the latter two of which are known to be intimately involved in tumour neo-
angiogenesis) and found CD105 expression to be adversely associated with overall 
survival in this cancer. Using in vitro and in vivo models, I then showed CD105 
conjugated MBs were able to specifically and significantly target tumour 
vasculature. 
 
Based on these results, it can be surmised that a targeted delivery platform using 
CD105 conjugated MBs can be developed to home in to CCA tissue. In addition to 
therapeutic blockade of CD105, these MBs could be further functionalised to carry a 
relevant payload such as an anti-NGAL molecule, which when driven into tumour 
tissue under the influence of a destructive US pulse would exert theragnostic 
effects.   
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There are however further questions that require clarification before such a platform 
sees fruition. The degree of off-target binding with such a system and the nature of 
any off-target effects are currently unknown, and merit further investigation. Whilst 
employing biomarkers and ligands that are relatively specific for tumour tissue 
greatly aids targeting, no currently known molecule is unique to tumour tissue. In 
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7.2 Appendix B: Ingredients for H69 (normal cholangiocyte 
cell line) culture medium 
 
 
 
 
 
